Document_and_Entity_Informatio
Document and Entity Information | 3 Months Ended | |
Dec. 31, 2013 | Jan. 31, 2014 | |
Document Document And Entity Information [Line Items] | ' | ' |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 31-Dec-13 | ' |
Document Fiscal Year Focus | '2014 | ' |
Document Fiscal Period Focus | 'Q1 | ' |
Trading Symbol | 'ARWR | ' |
Entity Registrant Name | 'ARROWHEAD RESEARCH CORP | ' |
Entity Central Index Key | '0000879407 | ' |
Current Fiscal Year End Date | '--09-30 | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Common Stock, Shares Outstanding | ' | 39,687,033 |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Dec. 31, 2013 | Sep. 30, 2013 |
CURRENT ASSETS | ' | ' |
Cash and cash equivalents | $59,713,424 | $19,114,444 |
Trade receivable | 75,000 | 75,000 |
Other receivables | 20,488 | 8,663 |
Prepaid expenses and other current assets | 689,954 | 615,351 |
Short term investments | 15,912,757 | 9,030,261 |
TOTAL CURRENT ASSETS | 76,411,623 | 28,843,719 |
PROPERTY AND EQUIPMENT | ' | ' |
Computers, office equipment and furniture | 323,376 | 323,376 |
Research equipment | 3,319,429 | 3,452,013 |
Software | 69,623 | 69,623 |
Leasehold improvements | 2,749,409 | 2,749,409 |
Property, Plant and Equipment, Gross, Total | 6,461,837 | 6,594,421 |
Less: Accumulated depreciation and amortization | -3,275,690 | -3,081,186 |
PROPERTY AND EQUIPMENT, NET | 3,186,147 | 3,513,235 |
OTHER ASSETS | ' | ' |
Patents and other intangible assets, net | 3,226,850 | 3,240,513 |
Investments | 9,867,857 | 1,732,164 |
TOTAL OTHER ASSETS | 13,094,707 | 4,972,677 |
TOTAL ASSETS | 92,692,477 | 37,329,631 |
CURRENT LIABILITIES | ' | ' |
Accounts payable | 589,348 | 1,199,632 |
Accrued expenses | 684,520 | 638,884 |
Accrued payroll and benefits | 678,035 | 905,771 |
Deferred revenue | 109,375 | 103,125 |
Derivative liabilities | 5,097,442 | 4,096,363 |
Capital lease obligation | 221,345 | 221,345 |
Notes payable | 1,050,000 | 971,557 |
Other current liabilities | 588,343 | 588,343 |
TOTAL CURRENT LIABILITIES | 9,018,408 | 8,725,020 |
LONG-TERM LIABILITIES | ' | ' |
Notes payable, net of current portion | ' | 50,000 |
Capital lease obligation, net of current portion | 1,006,398 | 1,061,113 |
Other non-current liabilities | 1,757,384 | 1,758,709 |
TOTAL LONG-TERM LIABILITIES | 2,763,782 | 2,869,822 |
Commitments and contingencies | ' | ' |
STOCKHOLDERS’ EQUITY | ' | ' |
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 51,291 and 9,900 shares issued and outstanding as of December 31, 2013 and September 30, 2013, respectively | 51 | 10 |
Common stock, $0.001 par value; 145,000,000 shares authorized; 39,002,152 and 32,489,444 shares issued and outstanding as of December 31, 2013 and September 30, 2013, respectively | 131,372 | 124,859 |
Additional paid-in capital | 259,369,442 | 193,514,766 |
Accumulated deficit during the development stage | -176,769,281 | -166,140,969 |
Total Arrowhead Research Corporation stockholders' equity | 82,731,584 | 27,498,666 |
Noncontrolling interest | -1,821,297 | -1,763,877 |
TOTAL STOCKHOLDERS’ EQUITY | 80,910,287 | 25,734,789 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $92,692,477 | $37,329,631 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parenthetical) (USD $) | Dec. 31, 2013 | Sep. 30, 2013 |
Statement Consolidated Balance Sheets Parenthetical [Line Items] | ' | ' |
Preferred stock, par value | $0.00 | $0.00 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 51,291 | 9,900 |
Preferred stock, shares outstanding | 51,291 | 9,900 |
Common stock, par value | $0.00 | $0.00 |
Common stock, shares authorized | 145,000,000 | 145,000,000 |
Common stock, shares issued | 39,002,152 | 32,489,444 |
Common stock, shares outstanding | 39,002,152 | 32,489,444 |
Consolidated_Statements_of_Ope
Consolidated Statements of Operations (USD $) | 3 Months Ended | 128 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Statement Consolidated Statements Of Operations [Line Items] | ' | ' | ' |
REVENUE | $43,750 | $159,016 | $4,472,850 |
OPERATING EXPENSES | ' | ' | ' |
Salaries and payroll-related costs | 2,081,791 | 1,629,423 | 35,141,590 |
General and administrative expenses | 913,784 | 917,676 | 35,755,863 |
Research and development | 3,133,014 | 1,576,666 | 54,457,389 |
Stock-based compensation | 521,138 | 395,675 | 15,638,877 |
Depreciation and amortization | 403,405 | 449,597 | 9,564,103 |
Impairment expense | ' | ' | 1,308,047 |
Contingent consideration - fair value adjustments | ' | ' | 1,421,652 |
TOTAL OPERATING EXPENSES | 7,053,132 | 4,969,037 | 153,287,521 |
OPERATING LOSS | -7,009,382 | -4,810,021 | -148,814,671 |
OTHER INCOME (EXPENSE) | ' | ' | ' |
Equity in income (loss) of unconsolidated affiliates | -138,456 | -63,557 | -1,743,004 |
Impairment of investment in unconsolidated affiliates | ' | ' | -1,642,775 |
Gain on purchase of Roche Madison | ' | ' | 1,576,107 |
Gain (loss) on sale of fixed assets, net | -53,562 | 18,493 | -1,336,415 |
Realized and unrealized gain (loss) in marketable securities | ' | ' | 62,954 |
Interest income (expense), net | 40,578 | 7,416 | 2,693,112 |
Change in value of derivatives | -3,519,579 | 44,275 | -5,538,564 |
Gain on sale of stock in subsidiary | ' | ' | 2,292,800 |
Other income (expense) | -5,331 | 22,685 | -753,306 |
TOTAL OTHER INCOME (EXPENSE) | -3,676,350 | 29,312 | -4,389,091 |
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES | -10,685,732 | -4,780,709 | -153,203,762 |
Provision for income taxes | ' | ' | ' |
LOSS FROM CONTINUING OPERATIONS | -10,685,732 | -4,780,709 | -153,203,762 |
Income (loss) from discontinued operations | ' | -18 | -47,546,996 |
Gain on disposal of discontinued operations | ' | ' | 4,708,588 |
NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS | ' | -18 | -42,838,408 |
NET LOSS | -10,685,732 | -4,780,727 | -196,042,170 |
Net loss attributable to noncontrolling interests | 57,420 | 166,568 | 19,436,849 |
NET LOSS ATTRIBUTABLE TO ARROWHEAD | ($10,628,312) | ($4,614,159) | ($176,605,321) |
NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD SHAREHOLDERS - BASIC AND DILUTED: | ($0.28) | ($0.33) | ' |
Weighted average shares outstanding - basic and diluted | 37,741,743 | 14,113,620 | ' |
Consolidated_Statement_of_Stoc
Consolidated Statement of Stockholders' Equity (USD $) | Total | Common Stock | Preferred Stock | Additional Paid-in Capital | Subscriptions Receivable | Accumulated Deficit during Development Stage | Noncontrolling Interest | Issued For Cash At Zero Point Zero One Dollars Per Unit | Issued For Cash At Zero Point Zero One Dollars Per Unit | Issued For Cash At Ten Dollar Per Unit | Issued For Cash At Ten Dollar Per Unit | Issued For Cash At Ten Dollar Per Unit | Stock Issuance Cost Charged To Additional Paid In Capital | Stock Issuance Cost Charged To Additional Paid In Capital | Issued For Marketable Securities At Ten Dollar Per Unit | Issued For Marketable Securities At Ten Dollar Per Unit | Issued For Marketable Securities At Ten Dollar Per Unit | Issued For Cash At Fifteen Dollar Per Unit | Issued For Cash At Fifteen Dollar Per Unit | Issued For Cash At Fifteen Dollar Per Unit | Equity Issued in Business Combination | Equity Issued in Business Combination | Equity Issued in Business Combination | Issued As Gift For Ten Dollar And Ninety Cents Per Share | Issued As Gift For Ten Dollar And Ninety Cents Per Share | Issued As Gift For Ten Dollar And Ninety Cents Per Share | Issued As Stock Issuance Cost At Fifteen Dollar Per Unit | Issued As Stock Issuance Cost At Fifteen Dollar Per Unit | Issued As Stock Issuance Cost At Fifteen Dollar Per Unit | Exercised At Two Dollar Per Share | Exercised At Two Dollar Per Share | Exercised At Two Dollar Per Share | Exercised At Ten Dollar Per Share | Exercised At Ten Dollar Per Share | Exercised At Ten Dollar Per Share | Exercised At Fifteen Dollar Per Share | Exercised At Fifteen Dollar Per Share | Exercised At Fifteen Dollar Per Share | Issued To Purchase Insert Therapeutics Share At Thirty Nine Dollars And Eighty Cents Per Share | Issued To Purchase Insert Therapeutics Share At Thirty Nine Dollars And Eighty Cents Per Share | Issued To Purchase Insert Therapeutics Share At Thirty Nine Dollars And Eighty Cents Per Share | Issued At Forty Eight Dollars And Eighty Cents Per Share | Issued At Forty Eight Dollars And Eighty Cents Per Share | Issued At Forty Eight Dollars And Eighty Cents Per Share | Issued At Thirty Eight Dollars And Forty Cents Per Share | Issued At Thirty Eight Dollars And Forty Cents Per Share | Issued At Thirty Eight Dollars And Forty Cents Per Share | Issued At Thirty Five Dollars Per Share | Issued At Thirty Five Dollars Per Share | Issued At Thirty Five Dollars Per Share | Issued At Fifty Nine Dollars And Ten Cents Per Share | Issued At Fifty Nine Dollars And Ten Cents Per Share | Issued At Fifty Nine Dollars And Ten Cents Per Share | Issued To Purchase Calando Pharmaceuticals Inc At Fifty One Dollars And Seventy Cents Per Share | Issued To Purchase Calando Pharmaceuticals Inc At Fifty One Dollars And Seventy Cents Per Share | Issued To Purchase Calando Pharmaceuticals Inc At Fifty One Dollars And Seventy Cents Per Share | Issued At Fifty Seven Dollars And Eighty Cents Per Share | Issued At Fifty Seven Dollars And Eighty Cents Per Share | Issued At Fifty Seven Dollars And Eighty Cents Per Share | Issued For Purchase Of Carbon Nanotechnologies Inc At Thirty Seven Dollars And Seventy Cents Per Share | Issued For Purchase Of Carbon Nanotechnologies Inc At Thirty Seven Dollars And Seventy Cents Per Share | Issued For Purchase Of Carbon Nanotechnologies Inc At Thirty Seven Dollars And Seventy Cents Per Share | Issued At Approximately Eighteen Dollar Per Share Net | Issued At Approximately Eighteen Dollar Per Share Net | Issued At Approximately Eighteen Dollar Per Share Net | Issued At Twenty Seven Dollars And Twenty Cents Per Share To Rice University | Issued At Twenty Seven Dollars And Twenty Cents Per Share To Rice University | Issued At Twenty Seven Dollars And Twenty Cents Per Share To Rice University | Issued At Twenty Eight Dollars And Thirty Cents Per Share To Purchase Shares Of Unidym Inc | Issued At Twenty Eight Dollars And Thirty Cents Per Share To Purchase Shares Of Unidym Inc | Issued At Twenty Eight Dollars And Thirty Cents Per Share To Purchase Shares Of Unidym Inc | Issued At Twenty Nine Dollars And Fifty Cents Per Share To Purchase Masa Energy Llc | Issued At Twenty Nine Dollars And Fifty Cents Per Share To Purchase Masa Energy Llc | Issued At Twenty Nine Dollars And Fifty Cents Per Share To Purchase Masa Energy Llc | Issued At Twenty One Dollars And Ninety Cents Per Share To Unidym For Acquisition Of Nanoconduction | Issued At Twenty One Dollars And Ninety Cents Per Share To Unidym For Acquisition Of Nanoconduction | Issued At Twenty One Dollars And Ninety Cents Per Share To Unidym For Acquisition Of Nanoconduction | Issued At Twenty One Dollars And Eighty Cents Per Share | Issued At Twenty One Dollars And Eighty Cents Per Share | Issued At Twenty One Dollars And Eighty Cents Per Share | Issued At Five Dollars And Fifty Cents Per Share To Unidym Stockholder In Exchange For Unidym S Shares | Issued At Five Dollars And Fifty Cents Per Share To Unidym Stockholder In Exchange For Unidym S Shares | Issued At Five Dollars And Fifty Cents Per Share To Unidym Stockholder In Exchange For Unidym S Shares | Issued At Five Dollars And Twenty Cents Per Share To Tel Ventures In Exchange For Unidym S Shares | Issued At Five Dollars And Twenty Cents Per Share To Tel Ventures In Exchange For Unidym S Shares | Issued At Five Dollars And Twenty Cents Per Share To Tel Ventures In Exchange For Unidym S Shares | Arrowheads Increase In Proportionate Share Of Calandos Equity | Arrowheads Increase In Proportionate Share Of Calandos Equity | Issued At Three Dollars Per Share | Issued At Three Dollars Per Share | Issued At Three Dollars Per Share | Issued To Unidym Stockholders In Exchange For Unidyms Shares | Issued To Unidym Stockholders In Exchange For Unidyms Shares | Issued To Unidym Stockholders In Exchange For Unidyms Shares | Issued To Unidym Stockholders In Exchange For Unidyms Shares | Issued at $6.34 per share | Issued at $6.34 per share | Issued at $6.34 per share | Issued at $13.12 per share | Issued at $13.12 per share | Issued at $13.12 per share | Issued To Calando Stockholders In Exchange For Calando S Shares | Issued To Calando Stockholders In Exchange For Calando S Shares | Issued To Calando Stockholders In Exchange For Calando S Shares | Issued To Calando Stockholders In Exchange For Calando S Shares | Issued at $3.80 per share | Issued at $3.80 per share | Issued at $3.80 per share | Issued at $3.80 per share | Issuance Of Common Stock For Subscription | Issuance Of Common Stock For Subscription | Issued at $3.70 per share | Issued at $3.70 per share | Issued at $3.70 per share | Issued at $4.00 per share | Issued at $4.00 per share | Issued at $4.00 per share | Issued at $6.23 per share | Issued at $6.23 per share | Issued at $6.23 per share | Issued at $5.11 per share | Issued at $5.11 per share | Issued at $5.11 per share | Issued at $2.76 per share | Issued at $2.76 per share | Issued at $2.76 per share | Issued at $2.76 per share | Issued Under Committed Capital Agreement | Issued Under Committed Capital Agreement | Preferred Stock Issued At Thousand Dollars Per Share | Preferred Stock Issued At Thousand Dollars Per Share | Preferred Stock Issued At Thousand Dollars Per Share | Issued at $4.49 per share | Issued at $4.49 per share | Issued at $4.49 per share | Issued at $2.26 per share | Issued at $2.26 per share | Issued at $2.26 per share | Issued at $2.12 per share | Issued at $2.12 per share | Issued at $2.12 per share | Issued at $1.83 per share | Issued at $1.83 per share | Issued at $1.83 per share | Issued At Five Dollar And Eighty Six Cents Per Share | Issued At Five Dollar And Eighty Six Cents Per Share | Issued At Five Dollar And Eighty Six Cents Per Share |
Common Stock | Common Stock | Additional Paid-in Capital | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Subscriptions Receivable | Noncontrolling Interest | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Noncontrolling Interest | Common Stock | Additional Paid-in Capital | Subscriptions Receivable | Additional Paid-in Capital | Subscriptions Receivable | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Subscriptions Receivable | Common Stock | Additional Paid-in Capital | Preferred Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | Common Stock | Additional Paid-in Capital | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Beginning Balance Amount at Sep. 30, 2002 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance and sold of Common Stock | ' | ' | ' | ' | ' | ' | ' | ' | 300,000 | ' | 168,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issuances | ' | ' | ' | ' | ' | ' | ' | 3,000 | 3,000 | 1,680,000 | 1,680 | 1,678,320 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issuance cost charged to additional paid-in capital | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -168,000 | -168,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -95,238 | ' | ' | ' | ' | -95,238 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Amount at Sep. 30, 2003 | 1,419,762 | 4,680 | ' | 1,510,320 | ' | -95,238 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Shares at Sep. 30, 2003 | ' | 468,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance and sold of Common Stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 47,500 | ' | ' | ' | ' | 50,000 | ' | ' | 660,879 | ' | ' | 70,553 | ' | ' | 15,000 | ' | ' | 35,623 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issuances | ' | ' | ' | ' | ' | ' | ' | ' | ' | 475,000 | 475 | 474,525 | -96,500 | -96,500 | 500,000 | 500 | 499,500 | 9,913,182 | 6,609 | 9,906,573 | -150,469 | 706 | -151,175 | 162,750 | 163 | 162,587 | 534,344 | 356 | 533,988 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issuance cost charged to additional paid-in capital | -991,318 | ' | ' | -991,318 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -751,255 | ' | ' | ' | ' | -2,528,954 | 1,777,699 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised | ' | 7,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,500 | ' | ' | 600 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised, Amount | 15,000 | 75 | ' | 14,925 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,000 | 75 | 14,925 | 6,000 | 6 | 5,994 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation | 175,653 | ' | ' | 175,653 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Amount at Sep. 30, 2004 | 11,227,149 | 13,645 | ' | 12,059,997 | ' | -2,624,192 | 1,777,699 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Shares at Sep. 30, 2004 | ' | 1,363,155 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance and sold of Common Stock | ' | 1,250 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 50,226 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issuances | 50,000 | 12 | ' | 49,988 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,000,000 | 502 | 1,999,498 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -6,733,427 | ' | ' | ' | ' | -6,854,918 | 121,491 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,500 | ' | ' | 1,381,289 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised, Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 25,000 | 25 | 24,975 | 20,719,335 | 13,813 | 20,705,522 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation | 508,513 | ' | ' | 508,513 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Adjustments to additional paid in capital, reallocation of noncontrolling interest | 230,087 | ' | ' | 230,087 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Amount at Sep. 30, 2005 | 28,026,657 | 27,997 | ' | 35,578,580 | ' | -9,479,110 | 1,899,190 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Shares at Sep. 30, 2005 | ' | 2,798,419 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance and sold of Common Stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20,485 | ' | ' | 1,500 | ' | ' | 559,000 | ' | ' | 2,536 | ' | ' | 20,838 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issuances | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,000,000 | 205 | 999,795 | 57,600 | 15 | 57,585 | 19,545,000 | 5,590 | 19,539,410 | 150,000 | 25 | 149,975 | 1,077,333 | 208 | 1,077,125 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -19,961,961 | ' | ' | ' | ' | -18,997,209 | -964,752 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised | ' | 11,579 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised, Amount | 341,537 | 116 | ' | 341,421 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation | 1,369,478 | ' | ' | 1,369,478 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Amount at Sep. 30, 2006 | 31,605,644 | 34,156 | ' | 59,113,369 | ' | -28,476,319 | 934,438 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Shares at Sep. 30, 2006 | ' | 3,414,359 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance and sold of Common Stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 284,945 | ' | ' | 143,122 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issuances | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,152,215 | 2,849 | 15,149,366 | 5,400,000 | 1,431 | 5,398,569 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -30,712,947 | ' | ' | ' | ' | -29,931,118 | -781,829 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised | ' | 18,616 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised, Amount | 434,727 | 186 | ' | 434,541 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation | 2,175,544 | ' | ' | 2,175,544 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Adjustments to additional paid in capital, reallocation of noncontrolling interest | 2,401,394 | ' | ' | 2,401,394 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Amount at Sep. 30, 2007 | 26,456,577 | 38,622 | ' | 84,672,783 | ' | -58,407,437 | 152,609 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Shares at Sep. 30, 2007 | ' | 3,861,042 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance and sold of Common Stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 386,399 | ' | ' | 5,000 | ' | ' | 7,055 | ' | ' | 10,505 | ' | ' | 11,416 | ' | ' | 1,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issuances | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,960,585 | 3,867 | 6,956,718 | 136,000 | 50 | 135,950 | 200,000 | 71 | 199,929 | 310,000 | 105 | 309,895 | 250,000 | 114 | 249,886 | 32,700 | 15 | 32,685 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -27,241,639 | ' | ' | ' | ' | -27,089,030 | -152,609 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised | ' | 10,536 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised, Amount | 290,027 | 106 | ' | 289,921 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation | 3,187,397 | ' | ' | 3,187,397 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Adjustments to additional paid in capital, reallocation of noncontrolling interest | 1,720,962 | ' | ' | 1,720,962 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Amount at Sep. 30, 2008 | 12,302,609 | 42,950 | ' | 97,756,126 | ' | -85,496,467 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Shares at Sep. 30, 2008 | ' | 4,293,452 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance and sold of Common Stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 205,839 | ' | ' | 222,222 | ' | ' | ' | ' | 919,664 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issuances | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,133,676 | 2,059 | 1,131,617 | 1,158,333 | 2,222 | 1,156,111 | ' | ' | 2,758,993 | 9,197 | 2,749,796 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -19,308,392 | ' | ' | ' | ' | -19,308,392 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation | 2,676,170 | ' | ' | 2,676,170 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Adjustments to additional paid in capital, reallocation of noncontrolling interest | 16,297 | ' | ' | 16,297 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,120,250 | 2,120,250 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Reclassification of former Unidym mezzanine debt to equity | 2,000,000 | ' | ' | 2,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of preferred stock in subsidiary | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 300,000 | -300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amortization of discount on Unidym Series D Preferred Stock | ' | ' | ' | 163,960 | ' | -163,960 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Amount at Sep. 30, 2009 | 4,857,936 | 56,428 | ' | 110,070,327 | -300,000 | -104,968,819 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Shares at Sep. 30, 2009 | ' | 5,641,177 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance and sold of Common Stock | ' | 225,189 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,318 | ' | ' | ' | ' | 508,343 | ' | ' | 659,299 | ' | ' | 122,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issuances | 1,066,050 | 2,250 | ' | 1,063,600 | ' | ' | 200 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 153 | -1,435 | ' | 1,282 | 3,222,896 | 5,083 | 3,217,813 | 7,868,578 | 6,593 | 7,861,985 | ' | 1,220 | -160,667 | 159,447 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -6,957,038 | ' | ' | ' | ' | -5,774,048 | -1,182,990 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised | ' | 688 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised, Amount | 7,631 | 7 | ' | 7,624 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation | 1,582,149 | ' | ' | 1,582,149 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of preferred stock in subsidiary | 300,000 | ' | ' | ' | 300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Divestiture of Unidym | 300,000 | ' | ' | 245,345 | ' | ' | 54,655 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Establish derivative liability | -4,169,907 | ' | ' | -4,169,907 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Amount at Sep. 30, 2010 | 8,078,295 | 71,734 | ' | 119,716,834 | ' | -110,742,867 | -967,406 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Shares at Sep. 30, 2010 | ' | 7,172,014 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance and sold of Common Stock | ' | 8,656 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,458,917 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issuances | 43,279 | 87 | ' | 43,192 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,643,684 | 14,574 | 4,629,110 | ' | 900,000 | -900,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -3,492,399 | ' | ' | ' | ' | -3,128,885 | -363,514 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised | ' | 2,700 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised, Amount | 13,884 | 27 | ' | 13,857 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation | 1,404,640 | ' | ' | 1,404,640 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Adjustments to additional paid in capital, reallocation of noncontrolling interest | ' | ' | ' | -849,707 | ' | ' | 849,707 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of preferred stock in subsidiary | 1,618,509 | ' | ' | 1,618,509 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Divestiture of Unidym | 254,275 | ' | ' | ' | ' | ' | 254,275 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Amount at Sep. 30, 2011 | 12,564,167 | 86,422 | ' | 127,476,436 | -900,000 | -113,871,752 | -226,938 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Shares at Sep. 30, 2011 | ' | 8,642,286 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance and sold of Common Stock | ' | 15,511 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,217,159 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 138,158 | ' | ' | ' | ' | ' | 675,000 | ' | ' | 100,000 | ' | ' | 83,211 | ' | ' | 97,831 | ' | ' | 2,260,869 | ' | ' | 68,926 | ' | ' | 1,015 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issuances | 50,406 | 16 | ' | 50,390 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,147,830 | 9,332 | 6,138,498 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 425,000 | 1,382 | 523,618 | -100,000 | ' | ' | 2,247,750 | 6,750 | 2,241,000 | 400,000 | 1,000 | 399,000 | 500,001 | 83 | 499,918 | 500,001 | 98 | 499,903 | 5,796,240 | 2,261 | 5,809,979 | -16,000 | 689 | -689 | 1,015,000 | 1 | 1,014,999 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -22,110,723 | ' | ' | ' | ' | -21,125,928 | -984,795 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised | 4,883 | 4,583 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised, Amount | 23,833 | 45 | ' | 23,788 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,000 | ' | ' | 8,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation | 1,241,404 | ' | ' | 1,241,404 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fractional shares redeemed in reverse stock split | ' | -131 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred stock converted to common stock, shares | ' | 275,782 | -1,015 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred stock converted to common stock | ' | 276 | -1 | -275 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Amount at Sep. 30, 2012 | 8,808,909 | 108,354 | ' | 145,917,968 | -1,016,000 | -134,997,680 | -1,203,733 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Shares at Sep. 30, 2012 | ' | 13,579,185 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance and sold of Common Stock | ' | 1,182,451 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,900 | ' | ' | 239,894 | ' | ' | 1,825,079 | ' | ' | 1,667,051 | ' | ' | 14,262,553 | ' | ' | ' | ' |
Stock issuances | 2,054,599 | 1,183 | ' | 2,053,416 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,900,000 | 10 | 9,899,990 | 986,049 | 240 | 985,809 | 3,816,468 | 1,825 | 3,814,643 | 3,256,859 | 1,667 | 3,255,192 | 25,459,499 | 14,263 | 25,445,236 | ' | ' | ' |
Net loss | -31,703,433 | ' | ' | ' | ' | -31,143,289 | -560,144 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised | 675 | 675 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised, Amount | 2,579 | 1 | ' | 2,578 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation | 1,536,271 | ' | ' | 1,536,271 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Subscription payment | 16,000 | ' | ' | ' | 16,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Subscription reversal, Shares | ' | -267,444 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Subscription reversal | ' | -2,674 | ' | -997,326 | 1,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Establish and settlements related to derivative liability | 1,600,989 | ' | ' | 1,600,989 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Amount at Sep. 30, 2013 | 25,734,789 | 124,859 | 10 | 193,514,766 | ' | -166,140,969 | -1,763,877 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Shares at Sep. 30, 2013 | ' | 32,489,444 | 9,900 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance and sold of Common Stock | ' | 848,961 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 46,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,071,672 | ' |
Stock issuances | 2,434,563 | 849 | ' | 2,433,714 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 46,000,000 | 46 | 45,999,954 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 14,060,112 | 3,072 | 14,057,040 |
Net loss | -10,685,732 | ' | ' | ' | ' | -10,628,312 | -57,420 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised | 62,825 | 73,496 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised, Amount | 326,917 | 73 | ' | 326,844 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation | 521,138 | ' | ' | 521,138 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred stock converted to common stock, shares | ' | 2,518,579 | -4,609 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred stock converted to common stock | ' | 2,519 | -5 | -2,514 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Establish and settlements related to derivative liability | 2,518,500 | ' | ' | 2,518,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Amount at Dec. 31, 2013 | $80,910,287 | $131,372 | $51 | $259,369,442 | ' | ($176,769,281) | ($1,821,297) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance Shares at Dec. 31, 2013 | ' | 39,002,152 | 51,291 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Consolidated_Statement_of_Stoc1
Consolidated Statement of Stockholders' Equity (Parenthetical) (USD $) | Sep. 30, 2003 | Sep. 30, 2004 | Sep. 30, 2003 | Sep. 30, 2004 | Sep. 30, 2004 | Sep. 30, 2004 | Sep. 30, 2004 | Sep. 30, 2004 | Sep. 30, 2005 | Sep. 30, 2004 | Sep. 30, 2005 | Sep. 30, 2005 | Sep. 30, 2006 | Sep. 30, 2006 | Sep. 30, 2006 | Sep. 30, 2006 | Sep. 30, 2006 | Sep. 30, 2007 | Sep. 30, 2007 | Sep. 30, 2008 | Sep. 30, 2008 | Sep. 30, 2008 | Sep. 30, 2008 | Sep. 30, 2008 | Sep. 30, 2008 | Sep. 30, 2009 | Sep. 30, 2009 | Sep. 30, 2009 | Sep. 30, 2010 | Sep. 30, 2010 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2012 | Sep. 30, 2012 | Sep. 30, 2012 | Sep. 30, 2012 | Sep. 30, 2012 | Dec. 31, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Dec. 31, 2013 |
Issued For Cash At Zero Point Zero One Dollars Per Unit | Issued For Cash At Ten Dollar Per Unit | Issued For Cash At Ten Dollar Per Unit | Issued For Marketable Securities At Ten Dollar Per Unit | Issued For Cash At Fifteen Dollar Per Unit | Issued As Gift For Ten Dollar And Ninety Cents Per Share | Issued As Stock Issuance Cost At Fifteen Dollar Per Unit | Exercised At Two Dollar Per Share | Exercised At Ten Dollar Per Share | Exercised At Ten Dollar Per Share | Exercised At Fifteen Dollar Per Share | Issued To Purchase Insert Therapeutics Share At Thirty Nine Dollars And Eighty Cents Per Share | Issued At Forty Eight Dollars And Eighty Cents Per Share | Issued At Thirty Eight Dollars And Forty Cents Per Share | Issued At Thirty Five Dollars Per Share | Issued At Fifty Nine Dollars And Ten Cents Per Share | Issued To Purchase Calando Pharmaceuticals Inc At Fifty One Dollars And Seventy Cents Per Share | Issued At Fifty Seven Dollars And Eighty Cents Per Share | Issued For Purchase Of Carbon Nanotechnologies Inc At Thirty Seven Dollars And Seventy Cents Per Share | Issued At Approximately Eighteen Dollar Per Share Net | Issued At Twenty Seven Dollars And Twenty Cents Per Share To Rice University | Issued At Twenty Eight Dollars And Thirty Cents Per Share To Purchase Shares Of Unidym Inc | Issued At Twenty Nine Dollars And Fifty Cents Per Share To Purchase Masa Energy Llc | Issued At Twenty One Dollars And Ninety Cents Per Share To Unidym For Acquisition Of Nanoconduction | Issued At Twenty One Dollars And Eighty Cents Per Share | Issued At Five Dollars And Fifty Cents Per Share To Unidym Stockholder In Exchange For Unidym S Shares | Issued At Five Dollars And Twenty Cents Per Share To Tel Ventures In Exchange For Unidym S Shares | Issued At Three Dollars Per Share | Issued at $6.34 per share | Issued at $13.12 per share | Issued at $3.80 per share | Issued at $3.80 per share | Issued at $3.70 per share | Issued at $4.00 per share | Issued at $6.23 per share | Issued at $5.11 per share | Issued at $2.76 per share | Preferred Stock Issued At Thousand Dollars Per Share | Preferred Stock Issued At Thousand Dollars Per Share | Preferred Stock Issued At Thousand Dollars Per Share | Issued at $4.49 per share | Issued at $2.26 per share | Issued at $2.12 per share | Issued at $1.83 per share | Issued at $5.86 per share | |
Common stock & warrants issued for cash, price per unit | $0.01 | $10 | $10 | $10 | $15 | $10.90 | $15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options, price per share | ' | ' | ' | ' | ' | ' | ' | $2 | $10 | $10 | $15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock issued, par value per share | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $39.80 | $48.80 | $38.40 | $35 | $59.10 | $51.70 | $57.80 | $37.70 | $18 | $27.20 | $28.30 | $29.50 | $21.90 | $21.80 | $5.50 | $5.20 | $3 | $6.34 | $13.12 | $3.80 | $3.80 | $3.70 | $4 | $6.23 | $5.11 | $2.76 | ' | ' | ' | $4.49 | $2.26 | $2.12 | $1.83 | $5.86 |
Preferred stock issued, par value per share | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1,000 | $1,000 | $1,000 | ' | ' | ' | ' | ' |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 3 Months Ended | 128 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
CASH FLOWS FROM OPERATING ACTIVITIES OF CONTINUING OPERATIONS: | ' | ' | ' |
Net loss | ($10,685,732) | ($4,780,727) | ($196,042,170) |
Net loss attributable to noncontrolling interests | 57,420 | 166,568 | 19,436,849 |
NET LOSS ATTRIBUTABLE TO ARROWHEAD | -10,628,312 | -4,614,159 | -176,605,321 |
(Income) loss from discontinued operations | ' | 18 | 42,838,408 |
Realized and unrealized (gain) loss on investments | ' | ' | -762,954 |
Charge for bad debt allowance | ' | ' | 2,497,300 |
(Gain) loss from sale of subsidiary | ' | ' | -306,344 |
(Gain) loss on purchase of Roche Madison | ' | ' | -1,576,107 |
(Gain) loss on disposal of fixed assets | 53,562 | -18,493 | 1,336,415 |
Stock issued for professional services | ' | ' | 741,632 |
Change in value of derivatives | 3,519,579 | -44,275 | 5,538,564 |
Contingent consideration - fair value adjustments | ' | ' | 1,421,652 |
Purchased in-process research and development | ' | ' | 15,851,555 |
Stock-based compensation | 521,138 | 395,675 | 15,638,877 |
Depreciation and amortization | 403,405 | 449,597 | 9,564,103 |
Amortization (accretion) of note discounts, net | 28,443 | 572 | 158,301 |
Gain on sale of stock in subsidiary | ' | ' | -2,292,800 |
Noncash impairment expense | ' | ' | 3,958,496 |
Equity in income (loss) of unconsolidated affiliates | ' | 63,557 | 963,407 |
Noncontrolling interest | -57,420 | -166,568 | -19,436,849 |
Changes in operating assets and liabilities: | ' | ' | ' |
Receivables | ' | -105,891 | 34,415 |
Other receivables | -11,825 | ' | -2,553,887 |
Prepaid expenses | -74,455 | 157,208 | -510,841 |
Other current assets | ' | -12,441 | -165,566 |
Accounts payable | -610,284 | -68,459 | 209,673 |
Accrued expenses | 56,648 | 111,865 | 805,477 |
Other liabilities | -222,811 | 14,208 | 719,440 |
NET CASH USED IN OPERATING ACTIVITIES OF CONTINUING OPERATIONS | -7,022,332 | -3,837,586 | -101,932,954 |
CASH FLOWS FROM INVESTING ACTIVITIES OF CONTINUING OPERATIONS: | ' | ' | ' |
Purchases of property and equipment | -116,215 | -9,439 | -4,458,404 |
Proceeds from sale of investments | ' | ' | 4,732,688 |
Proceeds from sale of fixed assets | ' | 121,418 | 522,192 |
Purchase of marketable securities | -19,075,306 | ' | -48,383,752 |
Proceeds from sale of marketable securities | 4,045,956 | ' | 22,934,181 |
Cash transferred in acquisitions/divestitures | ' | ' | -1,579,365 |
Purchase of MASA Energy, LLC | ' | ' | -250,000 |
Minority equity investment | ' | ' | -2,000,000 |
Cash paid for interest in Insert | ' | ' | -10,150,000 |
Cash obtained from interest in Insert | ' | ' | 10,529,594 |
Proceeds from sale of subsidiaries | ' | ' | 359,375 |
Payment for patents | ' | ' | -303,440 |
Restricted cash | ' | ' | 50,773 |
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES OF CONTINUING OPERATIONS | -15,145,565 | 111,979 | -27,996,158 |
CASH FLOWS FROM FINANCING ACTIVITIES OF CONTINUING OPERATIONS: | ' | ' | ' |
Principal payments on capital leases | -54,715 | -53,098 | -466,122 |
Proceeds from issuance of common stock, preferred stock and warrants, net | 62,821,592 | 3,332,467 | 213,580,607 |
Proceeds from issuance of Calando debt | ' | ' | 2,516,467 |
Proceeds from sale of stock in subsidiary | ' | ' | 20,902,100 |
NET CASH PROVIDED BY FINANCING ACTIVITIES OF CONTINUING OPERATIONS | 62,766,877 | 3,279,369 | 236,533,052 |
Cash flows from discontinued operations: | ' | ' | ' |
Operating cash flows | ' | -18 | -46,004,141 |
Investing cash flows | ' | ' | 790,625 |
Financing cash flows | ' | ' | -1,677,000 |
Net cash provided by (used in) discontinued operations: | ' | -18 | -46,890,516 |
NET INCREASE (DECREASE) IN CASH | 40,598,980 | -446,256 | 59,713,424 |
CASH AT BEGINNING OF PERIOD | 19,114,444 | 3,377,288 | ' |
CASH AT END OF PERIOD | 59,713,424 | 2,931,032 | 59,713,424 |
Supplementary disclosures: | ' | ' | ' |
Interest paid | 9,496 | 11,114 | 332,228 |
Taxes paid | ' | ' | $742,500 |
Consolidated_Statements_of_Cas1
Consolidated Statements of Cash Flows (Parenthetical) (USD $) | Mar. 31, 2010 | Mar. 23, 2005 | Feb. 28, 2010 | Nov. 30, 2009 | Mar. 31, 2006 | Sep. 30, 2010 | Apr. 20, 2007 | Sep. 28, 2009 | Apr. 23, 2008 | Sep. 22, 2009 | Jun. 11, 2009 | Nov. 30, 2009 | Jun. 25, 2009 | Sep. 30, 2009 | Apr. 29, 2008 | Oct. 21, 2011 |
Insert Therapeutics Inc | Calando Pharmaceuticals Inc | Calando Pharmaceuticals Inc | Calando Pharmaceuticals Inc | Calando Pharmaceuticals Inc | Carbon Nanotechnologies Inc | Unidym Inc | Unidym Inc | Unidym Inc | Unidym Inc | Unidym Inc | Unidym Inc | Unidym Inc | MASA Energy LLC | Roche Madison | ||
Series A Preferred Stock | Series E Preferred Stock | Series A Preferred Stock | Series A Preferred Stock | Series C Preferred Stock | Series C Preferred Stock | Series C One Preferred Stock | ||||||||||
Purchase of common shares | ' | 7,375,000 | 200,000 | 2,850,000 | 964,000 | 1,562.50 | ' | ' | 200,000 | ' | ' | ' | ' | ' | ' | ' |
Common stock, shares issued | 12,870 | 50,226 | 8,000 | 114,000 | 20,838 | ' | 143,122 | 64,227 | 7,054 | 9,149 | 132,462 | 15,317 | 194,444 | 27,777 | 10,504 | 1,288,158 |
Common stock value | ' | $2,000,000 | ' | $706,800 | $1,077,333 | ' | $5,400,000 | $398,209 | ' | $46,662 | $688,802 | $47,485 | $972,222 | $186,111 | $310,000 | ' |
Value of common stock purchased | ' | ' | ' | ' | 1,928,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 560,000 | ' |
Stock purchased by cash | ' | ' | 60,000 | ' | 850,667 | ' | ' | ' | 200,000 | ' | ' | ' | ' | ' | 250,000 | ' |
Warrants issued | ' | ' | 2,400 | 24,000 | ' | 390,625 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants purchased | ' | ' | ' | 600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock exercise value | ' | ' | $5 | ' | ' | $5 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants exercised | 24,788 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issue of promissory note to Roche | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $50,000 |
Organization_and_Significant_A
Organization and Significant Accounting Policies | 3 Months Ended |
Dec. 31, 2013 | |
Organization and Significant Accounting Policies | ' |
NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES | |
Nature of Business | |
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology. | |
Liquidity | |
Historically, the Company’s primary source of financing has been through the sale of securities of Arrowhead. Research and development activities have required significant capital investment since the Company’s inception and we expect our operations to continue to require cash investment in fiscal 2014 and beyond as the Company advances its research and development efforts, including clinical trials, and related drug manufacturing. | |
At December 31, 2013, the Company had $59.7 million in cash to fund operations. In addition to its cash resources, the Company has invested excess cash in investment grade commercial bonds maturing in less than 24 months. These bonds provide a source of liquidity, though the Company plans to hold them until maturity. At December 31, 2013, the Company had invested $25.7 million in bonds. During the three months ended December 31, 2013, the Company’s cash position increased by $40.6 million. The Company received cash from the issuance of equity of $60.0 million and cash from the exercise of warrants and options of $2.8 million during the three months ended December 31, 2013. Cash invested in fixed income investments totaled a net change of $15.0 million. During the three months ended December 31, 2013, the Company had cash outflow of $7.0 million related to its continuing operating activities and capital expenditures of $0.1 million. | |
Summary of Significant Accounting Policies | |
Principles of Consolidation—The consolidated financial statements include the accounts of Arrowhead and its Subsidiaries. Arrowhead’s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, and responsible for the Company’s research and development function. All significant intercompany accounts and transactions are eliminated in consolidation, and noncontrolling interests are accounted for in the Company’s financial statements. | |
Basis of Presentation—The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring accruals, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year. The September 30, 2013 balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. This financial information should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2013. Certain reclassifications have been made to prior period financial statements to conform to the current period presentation. | |
Use of Estimates—The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Actual results could differ from those estimates. | |
Cash and Cash Equivalents—The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had no restricted cash at December 31, 2013 and 2012. | |
Concentration of Credit Risk—The Company maintains several checking accounts for its operations at two financial institutions. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. | |
Investments—the Company invests excess cash balances in short-term and long-term marketable debt securities. Investments may consist of certificates of deposits, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with FASB ASC 320, Investments – Debt and Equity Securities. This statement requires certain securities to be classified into three categories: | |
Held-to-maturity—Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. | |
Trading Securities—Debt and equity securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. | |
Available-for-Sale—Debt and equity securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders’ equity. | |
The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. At December 31, 2013, the Company classified all of its investments as held-to-maturity. | |
Held-to-maturity investments are measured and recorded at amortized cost on the Company’s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. | |
As of December 31, 2013, all short-term investments were comprised of corporate bonds with maturity dates of less than one year. Certain investments maturing in excess of twelve months, but less than 24 months are classified as long-term investments. As of December 31, 2013, the amortized cost of such bonds was $25,750,603. For the three months ended December 31, 2013, gross unrealized losses were $217,216; there were no gross unrealized gains. The total fair value of the investments at December 31, 2013 was $25,533,387. | |
See further information regarding fair market value of marketable debt securities in Note 11 – Fair Value Measurements, such fair market data is obtained from independent pricing services. | |
Property and Equipment—Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. | |
Intangible Assets Subject to Amortization—At December 31, 2013, intangible assets subject to amortization included certain license agreements acquired through business combinations. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. | |
In-Process Research & Development (IPR&D)—IPR&D assets represent capitalized on-going research projects that Arrowhead acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of R&D efforts associated with the project. Upon successful completion of a project, Arrowhead will make a determination as to the then remaining useful life of the intangible asset and begin amortization. Based on early adoption of ASU 2012-02, Arrowhead tests its indefinite-lived assets for impairment at least annually, through a two-step process. The first step is a qualitative assessment to determine if it is more likely than not that the indefinite lived assets are impaired. Arrowhead considers relevant events and circumstances that could affect the inputs used to determine the fair value of the intangible assets. If the qualitative assessment indicates that it is more likely than not that the intangible assets is impaired, a second step is performed which is a quantitative test to determine the fair value of the intangible asset. If the carrying amount of the intangible assets exceeds its fair value, an impairment loss is recorded in the amount of that excess. If circumstances determine that it is appropriate, the Company may also elect to bypass step one, and proceed directly to the second step. | |
Contingent Consideration - The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event. For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. We record a contingent consideration obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates. Estimated payments are discounted using present value techniques to arrive at estimated fair value at the balance sheet date. Changes in the fair value of our contingent consideration obligations are recognized within our consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. | |
Minority Equity Investments—The Company’s had a minority equity investment in Leonardo, a privately held biotechnology company. This investment has been fully impaired and the net book value at December 31, 2013 is $0. The operations of Leonardo ceased in December 2013. | |
Noncontrolling Interests in Majority-Owned Subsidiaries—Operating losses applicable to majority-owned Calando, Ablaris and, prior to its disposal, Unidym have periodically exceeded the noncontrolling interests in the equity capital of either Subsidiary. Such excess losses applicable to the noncontrolling interests have been and are borne by the Company as there is no obligation of the noncontrolling interests to fund any losses in excess of their original investment. There is also no obligation or commitment on the part of the Company to fund operating losses of any Subsidiary whether wholly-owned or majority-owned. The Company allocates the noncontrolling interest’s share of net loss in excess of the noncontrolling interest’s initial investment in accordance with FASB ASC 810-10. | |
When there is a change in the Company’s proportionate ownership share of a development-stage Subsidiary resulting from additional equity transactions in a Subsidiary, the change is accounted for as an equity transaction in consolidation. To the extent that the increase in the calculated value of the Company’s interest in the equity of the Subsidiary exceeds the Company’s investment in the offering, that increase in value is referred to as the Company’s “increase in its proportionate share of the Subsidiary’s equity” and the amount is recorded as an increase in the Company’s Additional Paid-in Capital. | |
Revenue Recognition—Revenue from license fees are recorded when persuasive evidence of an arrangement exists, title has passed or services have been rendered, a price is fixed and determinable, and collection is reasonably assured. We may generate revenue from product sales, technology licenses, collaborative research and development arrangements, and research grants. Revenue under technology licenses and collaborative agreements typically consists of nonrefundable and/or guaranteed technology license fees, collaborative research funding and various milestone and future product royalty or profit-sharing payments. | |
Revenue associated with research and development funding payments under collaborative agreements, is recognized ratably over the relevant periods specified in the agreement, generally the research and development period. Revenue from up-front license fees, milestones and product royalties are recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Payments received in advance of recognition as revenue are recorded as deferred revenue. | |
Allowance for Doubtful Accounts—The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed. | |
Research and Development—Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10. | |
Earnings (Loss) per Share—Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options issued to employees and consultants and warrants to purchase Common Stock of the Company. | |
Stock-Based Compensation—The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. We use the Black-Scholes option valuation model to estimate the fair value of our stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. We use historical data among other information to estimate the expected price volatility and the expected forfeiture rate. | |
Derivative Assets and Liabilities - We account for warrants and other derivative financial instruments as either equity or assets/liabilities based upon the characteristics and provisions of each instrument. Warrants classified as equity are recorded as additional paid-in capital on our consolidated balance sheet and no further adjustments to their valuation are made. Some of our warrants were determined to be ineligible for equity classification because of provisions that may result in an adjustment to their exercise price. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as assets or liabilities are recorded on our consolidated balance sheet at their fair value on the date of issuance and are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. We estimate the fair value of these assets/liabilities using option pricing models that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life and risk-free interest rate. | |
Income Taxes—The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period. | |
Recently Issued Accounting Standards | |
In July 2012, the FASB issued ASU 2012-02, Testing Indefinite-Lived Intangible Assets for Impairment, which amended the guidance in ASU 2011-08 to simplify the testing of indefinite-lived intangible assets other than goodwill for impairment. ASU 2012-02 becomes effective for annual and interim impairment tests performed for fiscal years beginning on or after September 15, 2012 and earlier adoption is permitted. We adopted this standard in the third quarter of fiscal year 2012. We believe adoption did not have a material effect on our financial statements. | |
Note_Receivable
Note Receivable | 3 Months Ended |
Dec. 31, 2013 | |
Note Receivable | ' |
NOTE 2. NOTE RECEIVABLE | |
As part of the proceeds from the sale of Unidym in January 2011, Arrowhead received a Note Receivable from Wisepower (the “Wisepower Note”) in the face amount of $2.5 million. On January 24, 2013, the Company entered into an agreement to sell the Wisepower Note. As consideration for selling the Wisepower Note, the Company received 1,570,000 shares of Wisepower stock, (the “First Tranche”). Per the terms of the agreement, the Company was entitled to receive additional consideration (the “Second Tranche”) based on the proceeds realized from the First Tranche, at which time the Company would deliver the Wisepower Note to the Purchaser. | |
As of December 31, 2013, the Company sold all shares of Wisepower from the First Tranche, and realized approximately $1.4 million in proceeds. It is unclear when or if the Company will receive the Second Tranche. The Company recorded the $1.4 million proceeds realized from the First Tranche against the $2.5 million value of the Wisepower Note, and recorded a reserve for the balance of the receivable of $1.1 million in fiscal 2013. The carrying value of the Wisepower Note at December 31, 2013 is zero. | |
Investments
Investments | 3 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Investments | ' | |||||||||||||||
NOTE 3. INVESTMENTS | ||||||||||||||||
The Company invests its excess cash balances in short-term and long-term debt securities. Investments at December 31, 2013 consisted of corporate bonds with maturities remaining of less than two years at the time of purchase. The Company may also invest excess cash balances in certificates of deposit, money market accounts, US Treasuries, US government agency obligations, corporate debt securities, and/or commercial paper. The Company accounts for its investments in accordance with FASB ASC 320, Investments – Debt and Equity Securities. At December 31, 2013, all investments were classified as held-to-maturity securities. | ||||||||||||||||
The following tables summarize the Company’s short and long-term investments as of December 31, 2013, and September 30, 2013. | ||||||||||||||||
As of December 31, 2013 | ||||||||||||||||
Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | |||||||||||||
Commercial notes (due within one year) | $ | 15,912,757 | $ | — | $ | (103,924 | ) | $ | 15,808,833 | |||||||
Commercial notes (due after one year through two years) | $ | 9,837,846 | — | $ | (113,292 | ) | $ | 9,724,554 | ||||||||
Total | $ | 25,750,603 | $ | — | $ | (217,216 | ) | $ | 25,533,387 | |||||||
As of September 30, 2013 | ||||||||||||||||
Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | |||||||||||||
Commercial notes (due within one year) | $ | 9,030,261 | $ | 7,500 | $ | (39,281 | ) | $ | 8,998,480 | |||||||
Commercial notes (due after one year through two years) | $ | 1,702,153 | — | $ | (2,362 | ) | $ | 1,699,791 | ||||||||
Total | $ | 10,732,414 | $ | 7,500 | $ | (41,643 | ) | $ | 10,698,271 | |||||||
Acquisitions
Acquisitions | 3 Months Ended |
Dec. 31, 2013 | |
Acquisitions | ' |
NOTE 4. ACQUISITIONS | |
Roche Madison | |
On October 21, 2011, the Company entered into a Stock and Asset Purchase Agreement (the “RNAi Purchase Agreement”) with Hoffmann-La Roche Inc. and F Hoffmann-La Roche Ltd (collectively, “Roche”), pursuant to which the Company purchased from Roche (i) all of the outstanding common stock of Roche Madison Inc. (“Roche Madison”, now “Arrowhead Madison”) and (ii) the intellectual property rights then held by Roche related to its RNAi business and identified in the RNAi Purchase Agreement (the “Transaction”). In consideration for the purchase of Roche Madison and the Roche RNAi assets, the Company issued to Roche a promissory note with a principal value of $50,000 and 1,288,158 shares of Common Stock. | |
Pursuant to the RNAi Purchase Agreement, Roche has a right of first negotiation on certain product candidates developed by the Company and its affiliates relating to the purchased assets. If the Company proposes to out-license or enters into substantive negotiations to out-license, any Clinical Candidate or Existing Candidate (as such terms are defined in the RNAi Purchase Agreement), the Company must give notice of the Candidate it proposes to out-license and negotiate exclusively and in good faith with Roche for 90 days regarding the applicable out-license. This right of first negotiation applies to all Existing Candidates (as defined in the RNAi Purchase Agreement) and the first five Clinical Candidates for which the Company delivers notice to Roche and subsequently enters into an out-license. | |
In addition to the consideration paid by the Company as per the closing terms, the Company is obligated to make certain royalty and milestone payments to Roche upon the occurrence of certain events. For certain product candidates that are developed by the Company that are covered by a valid claim by the patent rights transferred in the Transaction for which the Company and Roche do not enter into a licensing arrangement, the Company will be obligated to pay a 3% royalty on Net Sales (as defined in the RNAi Purchase Agreement), provided that the royalty rate may be reduced or offset in certain circumstances. The obligation to pay royalties on such candidates will last until the later of (i) the expiration of the last to expire patent right related to such product candidate that was transferred in the Transaction and (ii) ten years after the first commercial sale of such product candidate. | |
The Company will also be obligated to make cash payments to Roche upon the achievement of various milestones for certain clinical candidates, for which the Company and Roche do not enter into a licensing arrangement, including the first regulatory approval in certain jurisdictions, and upon certain annual sales milestones for candidates that receive regulatory approval. The potential payments range from $2,500,000 to $6,000,000 per milestone. At the time of acquisition, the Company’s estimate of future payments for potential royalties and milestones had a net present value of $84,935 which was recorded as contingent consideration as a part of other noncurrent liabilities. Contingent consideration is calculated by modeling research and development activities for clinical candidates, forecasting timelines to market, and using “peak sales” estimate modeling, cash flows and potential milestone and royalty payments are calculated. The modeling assumes certain success rates, and discount factors related to riskiness of projects and the time value of money to calculate a net present value of future consideration payments to Roche. These estimates are based on many unknown variables that are difficult to estimate, and due to the extended process of drug development prior to marketing of drug candidates, the models must extend many years into the future. Such predictions are inherently uncertain. Each year, the Company re-evaluates its contingent consideration, and if material, makes adjustments to the recorded liability. Any adjustment to the contingent consideration liability is reflected in the Company’s Statement of Operations. During fiscal 2013, the contingent consideration liability was increased by $1.4 million, which is recorded as a part of other noncurrent liabilities on the Company’s Consolidated Balance Sheet. For additional information related to our valuation of this obligation, see Note 11, Fair Value Measurements. |
Intangible_Assets
Intangible Assets | 3 Months Ended | |||||||||||
Dec. 31, 2013 | ||||||||||||
Intangible Assets | ' | |||||||||||
NOTE 5. INTANGIBLE ASSETS | ||||||||||||
Intangible assets consist of in-process research and development (“IPR&D”) not subject to amortization, and other intangible assets subject to amortization, which were capitalized as a part of a business combination. | ||||||||||||
IPR&D represents projects that have not yet received regulatory approval and are required to be classified as indefinite assets until the successful completion or the abandonment of the associated R&D efforts. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until approval is obtained in one or more jurisdictions which, individually or combined, are expected to generate a significant portion of the total revenue expected to be earned by an IPR&D project. At that time, we will determine the useful life of the asset, reclassify the asset out of IPR&D and begin amortization. If the associated R&D effort is abandoned the related IPR&D assets will likely be written off and we would record an impairment loss. | ||||||||||||
Intangible assets subject to amortization include patents capitalized as part of a business combination as well as license agreements capitalized as part of a business combination from the acquisition of Roche Madison. | ||||||||||||
The license agreements are being amortized over the estimated life remaining at the time of acquisition which was 4 years. Patents are amortized over a period of three years to twenty years. The weighted average original amortization period is twelve years. Amortization of license agreements and patents is expected to be approximately $55,000 for fiscal years 2014 and 2015, $13,000 in 2016, and zero thereafter. | ||||||||||||
We review amounts capitalized as IPR&D for impairment at least annually in the fourth quarter, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In the event the carrying value of the assets is not expected to be recovered, the assets are written down to their estimated fair values. We continue to test our indefinite-lived IPR&D assets for potential impairment until the projects are completed or abandoned. | ||||||||||||
The following table provides details on our intangible asset balances: | ||||||||||||
Intangible assets | Intangible assets | Total | ||||||||||
not subject to | subject to | Intangible assets | ||||||||||
amortization | amortization | |||||||||||
Balance at September 30, 2011 | $ | - | $ | 1,731,211 | $ | 1,731,211 | ||||||
Additions—Madison acquisition | 944,935 | 230,000 | 1,174,935 | |||||||||
Additions—Alvos acquisition | 2,172,387 | - | 2,172,387 | |||||||||
Amortization | - | (293,964 | ) | (293,964 | ) | |||||||
Balance at September 30, 2012 | $ | 3,117,322 | $ | 1,667,247 | $ | 4,784,569 | ||||||
Impairment | - | (1,308,047 | ) | (1,308,047 | ) | |||||||
Amortization | - | (236,009 | ) | (236,009 | ) | |||||||
Balance at September 30, 2013 | $ | 3,117,322 | $ | 123,191 | $ | 3,240,513 | ||||||
Amortization | - | (13,663 | ) | (13,663 | ) | |||||||
Balance at December 31, 2013 | $ | 3,117,322 | $ | 109,528 | $ | 3,226,850 | ||||||
Investment_in_Subsidiaries
Investment in Subsidiaries | 3 Months Ended |
Dec. 31, 2013 | |
Investment in Subsidiaries | ' |
NOTE 6. INVESTMENT IN SUBSIDIARIES | |
In addition to 100% ownership interest in Arrowhead Madison Inc., Arrowhead also maintains majority ownership in Calando Pharmaceuticals, Ablaris Therapeutics, Inc., and a minority investment in Leonardo Biosystems, Inc. | |
Calando Pharmaceuticals, Inc. | |
Calando is a developer of polymer delivery systems for siRNA and small molecule based therapeutics. Calando’s current cash resources preclude additional development of its platform technology and therapeutic candidates. Arrowhead has determined that it will not provide substantial further investment to Calando based on Arrowhead evaluation of Calando’s development and business prospects and Calando has been unsuccessful in its efforts to obtain capital from other sources. Calando has ceased operations and terminated its technology license with the California Institute of Technology on which its siRNA therapeutic development efforts were based. | |
In 2009, Calando outlicensed its small molecule program to Cerulean Pharma, Inc., a Boston, MA-based biotech company which has continued the development of the program. Under the license, as the development program progresses, Calando could collect partnership, milestone and royalty programs from Cerulean. | |
Calando has an outstanding promissory note with a balance of principal and interest totaling $1,167,000 as of December 31, 2013. The promissory note became due November 26, 2013; see Note 7 for further information. | |
As of December 31, 2013, Calando owed to Arrowhead $4.5 million under a series of 8% simple interest notes and advances. It is unclear whether these notes will be repaid or converted to equity in the future. The balance of the notes and advances is eliminated in consolidation. In fiscal 2013, the Calando patent estate was returned to Caltech, and the Calando technology is not being pursued. | |
As of December 31, 2013, Arrowhead owned 79% of the outstanding shares of Calando and 76% on a fully diluted basis. | |
Ablaris Therapeutics, Inc. | |
Ablaris was formed and began operations in fiscal 2011, based on the license of certain anti-obesity technology developed at the MD Anderson Cancer Center at the University of Texas. During fiscal 2011, Ablaris raised $2.9 million in cash, of which $1.3 million was invested by Arrowhead and $1.6 million was invested by outside investors, through the issuance of Ablaris Series A Preferred stock. | |
As of December 31, 2013, Arrowhead owned 64% of the outstanding shares of Ablaris and 64% on a fully diluted basis. | |
Leonardo Biosystems, Inc. | |
Leonardo, a privately-held drug-delivery company ceased operations in December 2013. Arrowhead’s investment in Leonardo and its receivable from Leonardo have been fully reserved. |
Notes_Payable
Notes Payable | 3 Months Ended |
Dec. 31, 2013 | |
Notes Payable | ' |
NOTE 7. NOTES PAYABLE | |
On November 26, 2008, Calando entered into Unsecured Convertible Promissory Note Agreements (“Notes”) for $2.5 million with accredited investors and Arrowhead, which invested $200,000 in the Notes offering. Arrowhead subsequently invested an additional $600,000 in the same offering. Except for one Note in the principal amount of $500,000, all Notes and accrued interest were converted into a total of 2,950 shares of Calando Series A Preferred Stock on June 23, 2009. The remaining Note had a 10% interest rate, matured on November 26, 2010, and was renegotiated and extended until November 26, 2013. The terms of the new note include a 10% interest rate and require two times principal payment at maturity. The interest rate while the Note is in default is 15%. The Note became due on November 26, 2013, but was not repaid due to lack of cash resources at Calando. At December 31, 2013, the Note is reflected on the balance sheet at the maturity amount of $1.0 million. Accrued interest in the amount of $167,000 is reflected as a part of accrued expenses on the Company’s Consolidated Balance Sheet. |
Stockholders_Equity
Stockholders' Equity | 3 Months Ended | ||||||||||
Dec. 31, 2013 | |||||||||||
Stockholders' Equity | ' | ||||||||||
NOTE 8. STOCKHOLDERS’ EQUITY | |||||||||||
At December 31, 2013, the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001, and 5,000,000 shares of Preferred Stock, par value $0.001. | |||||||||||
At December 31, 2013, 39,002,152 shares of Common Stock were outstanding. Additionally, 51,291 shares of Preferred Stock were outstanding, including 5,291 shares of Series B Preferred Stock, convertible into 2,891,257 shares of Common Stock, and 46,000 shares of Series C Preferred Stock, convertible into 7,849,829 shares of Common Stock, (collectively, the “Outstanding Preferred Stock”). At December 31, 2013, 3,451,210 shares were reserved for issuance upon exercise of options granted under Arrowhead’s 2000 Stock Option Plan and 2004 Equity Incentive Plan, as well as for inducement grants made to new employees. | |||||||||||
The Outstanding Preferred Stock is convertible to Common Stock by its holder at its stated conversion price, though the Outstanding Preferred Stock is not convertible to the extent the holder would beneficially own more than 9.99% of the number of Common Stock immediately after the conversion. The holders of Outstanding Preferred Stock are eligible to vote with the Common Stock of the Company on an as-converted basis, but only to the extent they are eligible for conversion without exceeding the 9.99% ownership limitation. The Outstanding Preferred Stock does not carry a coupon, but the Outstanding Preferred Stock is entitled to receive dividends on a pari passu basis with Common Stock, when and if declared. In any liquidation or dissolution of the Company, the holders of Outstanding Preferred Stock are entitled to participate in the distribution of the assets, to the extent legally available for distribution, on a pari passu basis with the Common Stock. | |||||||||||
On October 20, 2011, the Company and Lincoln Park Capital Fund, LLC, an Illinois limited liability company (“LPC”) entered into a $15 million purchase agreement (the “Purchase Agreement”), whereby LPC agreed to purchase up to $15 million of Common Stock, subject to certain limitations, from time to time during the three-year term of the Purchase Agreement. The Company has the right, in its sole discretion, over a 36-month period to sell up to $15 million of Common Stock (subject to certain limitations) to LPC, depending on certain conditions as set forth in the Purchase Agreement. As of December 31, 2013, the Company had drawn $1 million from the facility. | |||||||||||
On October 21, 2011 and October 24, 2011, the Company entered into Subscription Agreements with certain accredited investors (the “Series A Purchasers”), pursuant to which the Company issued and sold an aggregate of 1,015 shares of Series A Preferred Convertible Stock, $0.001 par value per share, at a purchase price of $1,000 per share. The aggregate purchase price paid for the shares of Series A Preferred was $1,015,000. On February 16, 2012, upon approval by the Company’s shareholders, 1,015 shares of Arrowhead Series A Preferred Convertible Stock, $0.001 par value per share, were converted to 275,782 shares of Common Stock. | |||||||||||
On October 21, 2011, the Company entered into a Subscription Agreement with an accredited investor, pursuant to which the Company issued and sold an aggregate of 675,000 shares of Common Stock, $0.001 par value per share, at a purchase price of $3.70 per share. The aggregate purchase price paid by the purchaser for the shares of Common Stock is $2,497,500. | |||||||||||
On August 10, 2012 the Company sold 2,260,869 units at a price of $2.76 per unit. Each unit consisted of one share of common stock and a warrant to purchase 0.75 shares of common stock at an exercise price of $3.25. Gross proceeds from the offering were $6.2 million excluding offering fees and expenses. | |||||||||||
In December 2012, the Company sold 1,825,079 units at a price of $2.26 per unit. Each unit consisted of one share of common stock and a warrant to purchase 0.5 shares of common stock. Gross proceeds from the offering were $4.1 million excluding offering fees and expenses. The exercise price of these warrants was $1.83 as of September 30, 2013, and may decrease based on certain specified events. As a result, the Company determined these warrants were ineligible for equity classification. Refer to Note 11 for further discussion regarding these warrants. | |||||||||||
In January 2013, the Company sold 1,667,051 units at a price of $2.12 per unit. Each unit consisted of one share of common stock and a warrant to purchase 0.5 shares of common stock. Gross proceeds from the offering were $3.5 million excluding offering fees and expenses. The exercise price of these warrants was $1.83 as of September 30, 2013, and may decrease based on certain specified events. As a result, the Company determined these warrants were ineligible for equity classification. Refer to Note 11 for further discussion regarding these warrants. | |||||||||||
In May 2013, the Company sold 14.3 million shares of Arrowhead common stock at a price of $1.83 per share and 9,900 shares of Arrowhead series B convertible preferred stock at a price of $1,000 per share. The series B preferred stock is convertible into common stock at a conversion price of $1.83. Gross proceeds were $36 million. No warrants were issued in the May 2013 financing. | |||||||||||
On October 11, 2013, the Company sold 3,071,672 shares of common stock, at a price of $5.86 per share, and 46,000 shares of Series C Convertible Preferred Stock (the “Preferred Shares”), at a price of $1,000 per share. The Preferred Shares are convertible into shares of common stock at a conversion price of $5.86. The aggregate purchase price paid by the Purchasers for the Shares and Preferred Shares was $64,000,000 and the Company received net proceeds of approximately $60,000,000, after advisory fees and offering expenses. | |||||||||||
The following table summarizes information about warrants outstanding at December 31, 2013: | |||||||||||
Number of | Remaining | ||||||||||
Warrants | Life in Years | ||||||||||
Exercise prices | |||||||||||
$ | 70.6 | 94,897 | 3.4 | ||||||||
$ | 5 | 1,118,357 | 0.9 | ||||||||
$ | 5.09 | 341,021 | 0.9 | ||||||||
$ | 1.38 | 50,836 | 2 | ||||||||
$ | 4.16 | 1,000 | 3 | ||||||||
$ | 3.25 | 1,379,571 | 2.6 | ||||||||
$ | 2.12 | 75,000 | 4 | ||||||||
$ | 1.83 | 492,869 | 4 | ||||||||
Total warrants outstanding | 3,553,551 | ||||||||||
Leases
Leases | 3 Months Ended | |||
Dec. 31, 2013 | ||||
Leases | ' | |||
NOTE 9. LEASES | ||||
The Company leases office space for its corporate headquarters in Pasadena, California. The lease expires January 31, 2018. Rental costs are approximately $13,000 per month, increasing 3% annually. | ||||
The Company’s research facility in Madison, Wisconsin is leased through February 28, 2019. Monthly rental expense is approximately $22,000. Other monthly rental expenses include common area maintenance and real estate taxes totaling approximately $13,000 per month. Utilities costs are approximately $15,000 per month. Including monthly payments recorded under a capital lease of approximately $21,000, total monthly costs are approximately $71,000 per month. | ||||
Facility and equipment rent expense, related to continuing operations, for three months ended December 31, 2013 and 2012 was $130,000 and $145,000, respectively. From inception to date, rent expense was $4,790,000. | ||||
As of December 31, 2013, future minimum lease payments due in fiscal years under capitalized leases are as follows: | ||||
2014 (remainder of) | $ | 192,634 | ||
2015 | 256,846 | |||
2016 | 256,846 | |||
2017 | 256,846 | |||
2018 | 256,846 | |||
2019 and thereafter | 107,019 | |||
Less interest | (99,294 | ) | ||
Principal | 1,227,743 | |||
Less current portion | (221,345 | ) | ||
Noncurrent portion | $ | 1,006,398 | ||
As of December 31, 2013, future minimum lease payments due in fiscal years under operating leases are as follows: | ||||
2014 (remainder of) | $ | 325,672 | ||
2015 | 445,921 | |||
2016 | 457,961 | |||
2017 | 470,154 | |||
2018 | 359,370 | |||
2019 and thereafter | 125,415 | |||
Total | $ | 2,184,493 | ||
StockBased_Compensation
Stock-Based Compensation | 3 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Stock-Based Compensation | ' | |||||||||||||||
NOTE 10. STOCK-BASED COMPENSATION | ||||||||||||||||
Arrowhead has two plans that provide for equity-based compensation. Under the 2000 Stock Option Plan, 153,200 shares of Arrowhead’s Common Stock are reserved for issuance upon exercise of non-qualified stock options. No further grants can be made under the 2000 Stock Option Plan. The 2004 Equity Incentive Plan reserves 2,902,360 shares for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards by the Board of Directors to employees, consultants and others. As of December 31, 2013, there were options granted and outstanding to purchase 152,900 and 2,874,640 shares of Common Stock under the 2000 Stock Option Plan and the 2004 Equity Incentive Plan, respectively. Also, as of December 31, 2013, there were 395,950 shares reserved for options issued outside of equity compensation plans, as inducement grants to new employees. During three months ended December 31, 2013, No options were granted under the 2004 Equity Incentive Plan, and 105,000 options were granted outside of equity incentive plans as inducement stock options to new employees. | ||||||||||||||||
The following tables summarize information about stock options: | ||||||||||||||||
Number of | Weighted- | Weighted- | Aggregate | |||||||||||||
Options | Average | Average | Intrinsic | |||||||||||||
Outstanding | Exercise | Remaining | Value | |||||||||||||
Price | Contractual | |||||||||||||||
Per Share | Term | |||||||||||||||
Balance At September 30, 2011 | 729,096 | $ | 9.03 | |||||||||||||
Granted | 1,229,500 | 4.4 | ||||||||||||||
Cancelled | (42,919 | ) | 11.77 | |||||||||||||
Exercised | (4,883 | ) | 5.2 | |||||||||||||
Balance At September 30, 2012 | 1,910,794 | 6.1 | ||||||||||||||
Granted | 1,509,166 | 2.03 | ||||||||||||||
Cancelled | — | — | ||||||||||||||
Exercised | (675 | ) | 3.93 | |||||||||||||
Balance At September 30, 2013 | 3,419,285 | $ | 4.68 | |||||||||||||
Granted | 105,000 | 7.98 | ||||||||||||||
Cancelled | -37,970 | 4.77 | ||||||||||||||
Exercised | -62,825 | 4.83 | ||||||||||||||
Balance At December 31, 2013 | 3,423,490 | $ | 4.77 | 8.1 years | $ | 21,646,786 | ||||||||||
Exercisable At December 31, 2013 | 1,377,779 | $ | 7.25 | 7.6 years | $ | 7,038,191 | ||||||||||
Stock-based compensation expense for the three months ended December 31, 2013 and 2012 was $521,138 and $395,674, respectively. There is no income tax benefit as the Company is currently operating at a loss and an actual income tax benefit may not be realized. The loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. | ||||||||||||||||
The fair value of the options granted by Arrowhead for the three months ended December 31, 2013 and 2012 is estimated at $531,510 and $6,083, respectively. No Calando stock options were issued during the three months ended December 31, 2013 or 2012. | ||||||||||||||||
The intrinsic value of the options exercised during the three months ended December 31, 2013 and 2012 was $314,858 and $554, respectively. | ||||||||||||||||
As of December 31, 2013, the pre-tax compensation expense for all unvested stock options at Arrowhead in the amount of approximately $5,111,999 will be recognized in our results of operations over a weighted average period of 3.0 years. As of December 31, 2013, the pre-tax compensation expense for all unvested stock options at Calando in the amount of approximately $28,695 will be recognized in our results of operations over a weighted average period of 1.8 years. | ||||||||||||||||
The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by our stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. | ||||||||||||||||
The assumptions used to value stock options are as follows: | ||||||||||||||||
Three months ended December 31, | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Dividend yield | — | — | ||||||||||||||
Risk-free interest rate | 1.9 | % | 0.7% to 1.0% | |||||||||||||
Volatility | 69 | % | 69 | % | ||||||||||||
Expected life (in years) | 6.25 | 5.5 to 6.25 | ||||||||||||||
Weighted average grant date fair value per share of options granted | $ | 5.06 | $ | 1.51 | ||||||||||||
The dividend yield is zero as the Company currently does not pay a dividend. | ||||||||||||||||
The risk-free interest rate is based on the U.S. Treasury bond. | ||||||||||||||||
Volatility is estimated based on volatility average of the Company’s Common Stock price. |
Fair_Value_Measurements
Fair Value Measurements | 3 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Fair Value Measurements | ' | |||||||||||||||
NOTE 11. FAIR VALUE MEASUREMENTS | ||||||||||||||||
The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level 1 provides the most reliable measure of fair value while Level 3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows: | ||||||||||||||||
Level 1—Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities. | ||||||||||||||||
Level 2—Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly. | ||||||||||||||||
Level 3—Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management’s best estimate of what market participants would use in valuing the asset or liability at the measurement date. | ||||||||||||||||
The following table summarizes fair value measurements at December 31, 2013 and September 30, 2013 for assets and liabilities measured at fair value on a recurring basis: | ||||||||||||||||
December 31, 2013: | ||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Cash and cash equivalents | $ | 59,713,424 | $ | — | $ | — | $ | 59,713,424 | ||||||||
Derivative assets | $ | — | $ | — | $ | — | $ | — | ||||||||
Derivative liabilities | $ | — | $ | — | $ | 5,097,442 | $ | 5,097,442 | ||||||||
Acquisition related contingent consideration obligations | $ | — | $ | — | $ | 1,595,273 | $ | 1,595,273 | ||||||||
September 30, 2013: | ||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Cash and cash equivalents | $ | 19,114,444 | $ | — | $ | — | $ | 19,114,444 | ||||||||
Derivative assets | $ | — | $ | — | $ | — | $ | — | ||||||||
Derivative liabilities | $ | — | $ | — | $ | 4,096,363 | $ | 4,096,363 | ||||||||
Acquisition related contingent consideration obligations | $ | — | $ | — | $ | 1,595,273 | $ | 1,595,273 | ||||||||
The Company invests its excess cash balances in short and long-term corporate bonds, generally with remaining maturities of less than two years. At December 31, 2013, the Company had short-term investments of $15,912,757, and long-term investments of $9,837,846, for a total of $25,750,603. The fair value of its investment at December 31, 2013 was $25,533,387. The Company expects to hold such investments until maturity, and thus unrealized gains and losses from the fluctuations in the fair value of the securities are not likely to be realized. | ||||||||||||||||
As part of the proceeds from the sale of Unidym in January 2011, Arrowhead received a bond from Wisepower in the face amount of $2.5 million. The bond is convertible to Wisepower common stock at a price of $2.00 per share. The conversion feature is subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the conversion feature on the date of issuance was estimated using an option pricing model and recorded on the Company’s consolidated balance sheet as a derivative asset. The fair value of the conversion feature is estimated at the end of each reporting period and the change in the fair value of the conversion feature is recorded as a nonoperating gain/loss as change in value of derivatives in Company’s Consolidated Statement of Operations. During the quarter ended March 31, 2013, the trading of Wisepower stock was halted. Trading resumed in July 2013, but the trading price is significantly below the conversion price. During fiscal 2013, the Company determined that the probability of realizing value from the conversion feature was remote, and the derivative asset value was reduced to zero. | ||||||||||||||||
During the three months ended December 31, 2013, there was no change in the fair value of the derivative asset. | ||||||||||||||||
The assumptions used in valuing the derivative asset were not applicable as the value has been determined to be zero at December 31, 2013 and September 30, 2013. | ||||||||||||||||
December 31, 2013 | September 30, 2013 | |||||||||||||||
Risk free interest rate | — | — | ||||||||||||||
Expected life | — | — | ||||||||||||||
Dividend yield | — | — | ||||||||||||||
Volatility | — | — | ||||||||||||||
The following is a reconciliation of the derivative asset: | ||||||||||||||||
Value at September 30, 2012 | $ | 250,250 | ||||||||||||||
Receipt of instruments | — | |||||||||||||||
Decrease in value | (250,250 | ) | ||||||||||||||
Net settlements | — | |||||||||||||||
Value at September 30, 2013 | $ | — | ||||||||||||||
Receipt of instruments | — | |||||||||||||||
Decrease in value | — | |||||||||||||||
Net settlements | — | |||||||||||||||
Value at December 31, 2013 | $ | — | ||||||||||||||
As part of an equity financing in June 2010, Arrowhead issued warrants to acquire up to 329,649 shares of Common Stock (the “2010 Warrants”), of which 50,836 warrants were outstanding at December 31, 2013, which contain a mechanism to adjust the strike price upon the issuance of certain dilutive equity securities. If during the term of the 2010 Warrants, the Company issues Common Stock at a price lower than the exercise price of the 2010 Warrants, the exercise price of the 2010 Warrants would be reduced to the amount equal to the issuance price of the Common Stock. Similarly, as part of a financing in December 2012, Arrowhead issued warrants to acquire up to 912,543 shares of Common Stock (the “2012 Warrants”) of which 324,461 warrants were outstanding at December 31, 2013, which contain a mechanism to adjust the strike price upon the issuance of certain dilutive equity securities. If during the term of the 2012 Warrants, the Company issues Common Stock at a price lower than the exercise price of the 2012 Warrants, the exercise price of the 2012 Warrants would be reduced to the amount equal to the issuance price of the Common Stock. Further, as part of a financing in January 2013, Arrowhead issued warrants to acquire up to 833,530 shares of Common Stock (the “2013 Warrants”) of which 168,408 warrants were outstanding at December 31, 2013 which contain a mechanism to adjust the strike price upon the issuance of certain dilutive equity securities. If during the term of the 2013 Warrants, the Company issues Common Stock at a price lower than the exercise price of the 2013 Warrants, the exercise price of the 2013 Warrants would be reduced to the amount equal to the issuance price of the Common Stock. As a result of these features, the 2010 Warrants, the 2012 Warrants, and the 2013 Warrants are subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the Warrants on the date of issuance was estimated using an option pricing model and recorded on the Company’s consolidated balance sheet as a derivative liability. The fair value of the Warrants is estimated at the end of each reporting period and the change in the fair value of the Warrants is recorded as a nonoperating gain or loss in the Company’s consolidated statement of operations. During the three months ended December 31, 2013, the Company recorded a non-cash loss from the change in fair value of the derivative liability of $3,519,579. | ||||||||||||||||
The assumptions used in valuing the derivative liability were as follows: | ||||||||||||||||
2010 Warrants | December 31, 2013 | September 30, 2013 | ||||||||||||||
Risk free interest rate | 0.38% | 0.33% | ||||||||||||||
Expected life | 2.0 Years | 2.2 Years | ||||||||||||||
Dividend yield | None | None | ||||||||||||||
Volatility | 69% | 69% | ||||||||||||||
2012 Warrants | 31-Dec-13 | 30-Sep-13 | ||||||||||||||
Risk free interest rate | 1.27% | 1.39% | ||||||||||||||
Expected life | 4.0 Years | 4.2 Years | ||||||||||||||
Dividend yield | None | None | ||||||||||||||
Volatility | 69% | 69% | ||||||||||||||
2013 Warrants | 31-Dec-13 | 30-Sep-13 | ||||||||||||||
Risk free interest rate | 1.27% | 1.39% | ||||||||||||||
Expected life | 4.1 Years | 4.3 Years | ||||||||||||||
Dividend yield | None | None | ||||||||||||||
Volatility | 69% | 69% | ||||||||||||||
The following is a reconciliation of the derivative liability related to these warrants: | ||||||||||||||||
Value at September 30, 2012 | $ | 626,195 | ||||||||||||||
Issuance of instruments | 2,153,819 | |||||||||||||||
Change in value | 5,066,591 | |||||||||||||||
Net settlements | (3,754,808 | ) | ||||||||||||||
Value at September 30, 2013 | $ | 4,091,797 | ||||||||||||||
Issuance of instruments | — | |||||||||||||||
Change in value | 3,507,496 | |||||||||||||||
Net settlements | -2,518,502 | |||||||||||||||
Value at December 31, 2013 | $ | 5,080,791 | ||||||||||||||
In conjunction with the financing of Ablaris in fiscal 2011, Arrowhead sold exchange rights to certain investors whereby the investors have the right to exchange their shares of Ablaris for a prescribed number of Arrowhead shares based upon a predefined ratio. The exchange rights have a seven-year term. During the first year, the exchange right allows the holder to exchange one Ablaris share for 0.06 Arrowhead shares (as adjusted for a subsequent reverse stock split). This ratio declines to 0.04 in the second year, 0.03 in the third year and 0.02 in the fourth year. In the fifth year and beyond the exchange ratio is 0.01. Exchange rights for 675,000 Ablaris shares were sold in fiscal 2011, and remain outstanding at December 31, 2013. The exchange rights are subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the exchange rights on the date of issuance was estimated using an option pricing model and recorded on the Company’s consolidated balance sheet as a derivative liability. The fair value of the exchange rights is estimated at the end of each reporting period and the change in the fair value of the exchange rights is recorded as a nonoperating gain or loss in the Company’s Consolidated Statement of Operations. During the three months ended December 31, 2013, the Company recorded a non-cash loss from the change in fair value of the derivative liability of $12,082. | ||||||||||||||||
The assumptions used in valuing the derivative liability were as follows: | ||||||||||||||||
December 31, 2013 | September 30, 2013 | |||||||||||||||
Risk free interest rate | 1.27% | 1.39% | ||||||||||||||
Expected life | 4.0 Years | 4.3 Years | ||||||||||||||
Dividend yield | None | None | ||||||||||||||
Volatility | 69% | 69% | ||||||||||||||
The following is a reconciliation of the derivative liability related to these exchange rights: | ||||||||||||||||
Value at September 30, 2012 | $ | 10,375 | ||||||||||||||
Issuance of instruments | — | |||||||||||||||
Change in value | (5,806 | ) | ||||||||||||||
Net settlements | — | |||||||||||||||
Value at September 30, 2013 | $ | 4,569 | ||||||||||||||
Issuance of instruments | — | |||||||||||||||
Change in value | 12,082 | |||||||||||||||
Net settlements | — | |||||||||||||||
Value at December 31, 2013 | $ | 16,651 | ||||||||||||||
The derivative assets/liabilities are estimated using option pricing models that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life and risk-free interest rate. Changes in the assumptions used could have a material impact on the resulting fair value. The primary input affecting the value of our derivatives liabilities is the Company’s stock price. Other inputs have a comparatively insignificant effect. | ||||||||||||||||
During fiscal 2012, contingent consideration was recorded upon the acquisitions of Roche Madison Inc. and Alvos Therapeutics, Inc., totaling $173,621. The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. Estimating timing to complete the development, and obtain approval of products is difficult, and there are inherent uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. Changes in the fair value of the contingent consideration obligations are recorded in our consolidated statement of operations. | ||||||||||||||||
The following is a reconciliation of contingent consideration fair value. | ||||||||||||||||
Value at September 30, 2012 | $ | 173,621 | ||||||||||||||
Purchase price contingent consideration | — | |||||||||||||||
Contingent consideration payments | — | |||||||||||||||
Change in fair value of contingent consideration | 1,421,652 | |||||||||||||||
Value at September 30, 2013 | $ | 1,595,273 | ||||||||||||||
Purchase price contingent consideration | — | |||||||||||||||
Contingent consideration payments | — | |||||||||||||||
Change in fair value of contingent consideration | — | |||||||||||||||
Value at December 31, 2013 | $ | 1,595,273 | ||||||||||||||
The fair value of contingent consideration obligations is estimated through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates. Estimated payments are discounted using present value techniques to arrive at estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. Each of these assumptions can have a significant impact on the calculation of contingent consideration. | ||||||||||||||||
The carrying amounts of the Company’s other financial instruments, which include accounts receivable, accounts payable, and accrued expenses approximate their respective fair values due to the relatively short-term nature of these instruments. The carrying value of the Company’s debt obligations approximates fair value based on market interest rates. |
Organization_and_Significant_A1
Organization and Significant Accounting Policies (Policies) | 3 Months Ended |
Dec. 31, 2013 | |
Nature of Business | ' |
Nature of Business | |
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology. | |
Liquidity | ' |
Liquidity | |
Historically, the Company’s primary source of financing has been through the sale of securities of Arrowhead. Research and development activities have required significant capital investment since the Company’s inception and we expect our operations to continue to require cash investment in fiscal 2014 and beyond as the Company advances its research and development efforts, including clinical trials, and related drug manufacturing. | |
At December 31, 2013, the Company had $59.7 million in cash to fund operations. In addition to its cash resources, the Company has invested excess cash in investment grade commercial bonds maturing in less than 24 months. These bonds provide a source of liquidity, though the Company plans to hold them until maturity. At December 31, 2013, the Company had invested $25.7 million in bonds. During the three months ended December 31, 2013, the Company’s cash position increased by $40.6 million. The Company received cash from the issuance of equity of $60.0 million and cash from the exercise of warrants and options of $2.8 million during the three months ended December 31, 2013. Cash invested in fixed income investments totaled a net change of $15.0 million. During the three months ended December 31, 2013, the Company had cash outflow of $7.0 million related to its continuing operating activities and capital expenditures of $0.1 million. | |
Principles of Consolidation | ' |
Principles of Consolidation—The consolidated financial statements include the accounts of Arrowhead and its Subsidiaries. Arrowhead’s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, and responsible for the Company’s research and development function. All significant intercompany accounts and transactions are eliminated in consolidation, and noncontrolling interests are accounted for in the Company’s financial statements. | |
Basis of Presentation | ' |
Basis of Presentation—The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring accruals, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year. The September 30, 2013 balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. This financial information should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2013. Certain reclassifications have been made to prior period financial statements to conform to the current period presentation. | |
Use of Estimates | ' |
Use of Estimates—The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Actual results could differ from those estimates. | |
Cash and Cash Equivalents | ' |
Cash and Cash Equivalents—The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had no restricted cash at December 31, 2013 and 2012. | |
Concentration of Credit Risk | ' |
Concentration of Credit Risk—The Company maintains several checking accounts for its operations at two financial institutions. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. | |
Investments | ' |
Investments—the Company invests excess cash balances in short-term and long-term marketable debt securities. Investments may consist of certificates of deposits, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with FASB ASC 320, Investments – Debt and Equity Securities. This statement requires certain securities to be classified into three categories: | |
Held-to-maturity—Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. | |
Trading Securities—Debt and equity securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. | |
Available-for-Sale—Debt and equity securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders’ equity. | |
The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. At December 31, 2013, the Company classified all of its investments as held-to-maturity. | |
Held-to-maturity investments are measured and recorded at amortized cost on the Company’s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. | |
As of December 31, 2013, all short-term investments were comprised of corporate bonds with maturity dates of less than one year. Certain investments maturing in excess of twelve months, but less than 24 months are classified as long-term investments. As of December 31, 2013, the amortized cost of such bonds was $25,750,603. For the three months ended December 31, 2013, gross unrealized losses were $217,216; there were no gross unrealized gains. The total fair value of the investments at December 31, 2013 was $25,533,387. | |
See further information regarding fair market value of marketable debt securities in Note 11 – Fair Value Measurements, such fair market data is obtained from independent pricing services. | |
Property and Equipment | ' |
Property and Equipment—Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. | |
Intangible Assets subject to amortization | ' |
Intangible Assets Subject to Amortization—At December 31, 2013, intangible assets subject to amortization included certain license agreements acquired through business combinations. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. | |
In-Process Research & Development (IPR&D) | ' |
In-Process Research & Development (IPR&D)—IPR&D assets represent capitalized on-going research projects that Arrowhead acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of R&D efforts associated with the project. Upon successful completion of a project, Arrowhead will make a determination as to the then remaining useful life of the intangible asset and begin amortization. Based on early adoption of ASU 2012-02, Arrowhead tests its indefinite-lived assets for impairment at least annually, through a two-step process. The first step is a qualitative assessment to determine if it is more likely than not that the indefinite lived assets are impaired. Arrowhead considers relevant events and circumstances that could affect the inputs used to determine the fair value of the intangible assets. If the qualitative assessment indicates that it is more likely than not that the intangible assets is impaired, a second step is performed which is a quantitative test to determine the fair value of the intangible asset. If the carrying amount of the intangible assets exceeds its fair value, an impairment loss is recorded in the amount of that excess. If circumstances determine that it is appropriate, the Company may also elect to bypass step one, and proceed directly to the second step. | |
Contingent Consideration | ' |
Contingent Consideration - The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event. For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. We record a contingent consideration obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates. Estimated payments are discounted using present value techniques to arrive at estimated fair value at the balance sheet date. Changes in the fair value of our contingent consideration obligations are recognized within our consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. | |
Minority Equity Investments | ' |
Minority Equity Investments—The Company’s had a minority equity investment in Leonardo, a privately held biotechnology company. This investment has been fully impaired and the net book value at December 31, 2013 is $0. The operations of Leonardo ceased in December 2013. | |
Noncontrolling Interests in Majority-Owned Subsidiaries | ' |
Noncontrolling Interests in Majority-Owned Subsidiaries—Operating losses applicable to majority-owned Calando, Ablaris and, prior to its disposal, Unidym have periodically exceeded the noncontrolling interests in the equity capital of either Subsidiary. Such excess losses applicable to the noncontrolling interests have been and are borne by the Company as there is no obligation of the noncontrolling interests to fund any losses in excess of their original investment. There is also no obligation or commitment on the part of the Company to fund operating losses of any Subsidiary whether wholly-owned or majority-owned. The Company allocates the noncontrolling interest’s share of net loss in excess of the noncontrolling interest’s initial investment in accordance with FASB ASC 810-10. | |
When there is a change in the Company’s proportionate ownership share of a development-stage Subsidiary resulting from additional equity transactions in a Subsidiary, the change is accounted for as an equity transaction in consolidation. To the extent that the increase in the calculated value of the Company’s interest in the equity of the Subsidiary exceeds the Company’s investment in the offering, that increase in value is referred to as the Company’s “increase in its proportionate share of the Subsidiary’s equity” and the amount is recorded as an increase in the Company’s Additional Paid-in Capital. | |
Revenue Recognition | ' |
Revenue Recognition—Revenue from license fees are recorded when persuasive evidence of an arrangement exists, title has passed or services have been rendered, a price is fixed and determinable, and collection is reasonably assured. We may generate revenue from product sales, technology licenses, collaborative research and development arrangements, and research grants. Revenue under technology licenses and collaborative agreements typically consists of nonrefundable and/or guaranteed technology license fees, collaborative research funding and various milestone and future product royalty or profit-sharing payments. | |
Revenue associated with research and development funding payments under collaborative agreements, is recognized ratably over the relevant periods specified in the agreement, generally the research and development period. Revenue from up-front license fees, milestones and product royalties are recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Payments received in advance of recognition as revenue are recorded as deferred revenue. | |
Allowance for Doubtful Accounts | ' |
Allowance for Doubtful Accounts—The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed. | |
Research and Development | ' |
Research and Development—Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10. | |
Earnings (Loss) per Share | ' |
Earnings (Loss) per Share—Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options issued to employees and consultants and warrants to purchase Common Stock of the Company. | |
Stock-Based Compensation | ' |
Stock-Based Compensation—The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. We use the Black-Scholes option valuation model to estimate the fair value of our stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. We use historical data among other information to estimate the expected price volatility and the expected forfeiture rate. | |
Derivative Assets and Liabilities | ' |
Derivative Assets and Liabilities - We account for warrants and other derivative financial instruments as either equity or assets/liabilities based upon the characteristics and provisions of each instrument. Warrants classified as equity are recorded as additional paid-in capital on our consolidated balance sheet and no further adjustments to their valuation are made. Some of our warrants were determined to be ineligible for equity classification because of provisions that may result in an adjustment to their exercise price. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as assets or liabilities are recorded on our consolidated balance sheet at their fair value on the date of issuance and are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. We estimate the fair value of these assets/liabilities using option pricing models that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life and risk-free interest rate. | |
Income Taxes | ' |
Income Taxes—The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period. | |
Recently Issued Accounting Standards | ' |
Recently Issued Accounting Standards | |
In July 2012, the FASB issued ASU 2012-02, Testing Indefinite-Lived Intangible Assets for Impairment, which amended the guidance in ASU 2011-08 to simplify the testing of indefinite-lived intangible assets other than goodwill for impairment. ASU 2012-02 becomes effective for annual and interim impairment tests performed for fiscal years beginning on or after September 15, 2012 and earlier adoption is permitted. We adopted this standard in the third quarter of fiscal year 2012. We believe adoption did not have a material effect on our financial statements. | |
Investments_Tables
Investments (Tables) | 3 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Summary of Short and Long-term Investments | ' | |||||||||||||||
The following tables summarize the Company’s short and long-term investments as of December 31, 2013, and September 30, 2013. | ||||||||||||||||
As of December 31, 2013 | ||||||||||||||||
Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | |||||||||||||
Commercial notes (due within one year) | $ | 15,912,757 | $ | — | $ | (103,924 | ) | $ | 15,808,833 | |||||||
Commercial notes (due after one year through two years) | $ | 9,837,846 | — | $ | (113,292 | ) | $ | 9,724,554 | ||||||||
Total | $ | 25,750,603 | $ | — | $ | (217,216 | ) | $ | 25,533,387 | |||||||
As of September 30, 2013 | ||||||||||||||||
Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | |||||||||||||
Commercial notes (due within one year) | $ | 9,030,261 | $ | 7,500 | $ | (39,281 | ) | $ | 8,998,480 | |||||||
Commercial notes (due after one year through two years) | $ | 1,702,153 | — | $ | (2,362 | ) | $ | 1,699,791 | ||||||||
Total | $ | 10,732,414 | $ | 7,500 | $ | (41,643 | ) | $ | 10,698,271 | |||||||
Intangible_Assets_Tables
Intangible Assets (Tables) | 3 Months Ended | |||||||||||
Dec. 31, 2013 | ||||||||||||
Schedule of Intangible Asset | ' | |||||||||||
The following table provides details on our intangible asset balances: | ||||||||||||
Intangible assets | Intangible assets | Total | ||||||||||
not subject to | subject to | Intangible assets | ||||||||||
amortization | amortization | |||||||||||
Balance at September 30, 2011 | $ | - | $ | 1,731,211 | $ | 1,731,211 | ||||||
Additions—Madison acquisition | 944,935 | 230,000 | 1,174,935 | |||||||||
Additions—Alvos acquisition | 2,172,387 | - | 2,172,387 | |||||||||
Amortization | - | (293,964 | ) | (293,964 | ) | |||||||
Balance at September 30, 2012 | $ | 3,117,322 | $ | 1,667,247 | $ | 4,784,569 | ||||||
Impairment | - | (1,308,047 | ) | (1,308,047 | ) | |||||||
Amortization | - | (236,009 | ) | (236,009 | ) | |||||||
Balance at September 30, 2013 | $ | 3,117,322 | $ | 123,191 | $ | 3,240,513 | ||||||
Amortization | - | (13,663 | ) | (13,663 | ) | |||||||
Balance at December 31, 2013 | $ | 3,117,322 | $ | 109,528 | $ | 3,226,850 | ||||||
Stockholders_Equity_Tables
Stockholders' Equity (Tables) | 3 Months Ended | ||||||||||
Dec. 31, 2013 | |||||||||||
Summary of Information About Warrants | ' | ||||||||||
The following table summarizes information about warrants outstanding at December 31, 2013: | |||||||||||
Number of | Remaining | ||||||||||
Warrants | Life in Years | ||||||||||
Exercise prices | |||||||||||
$ | 70.6 | 94,897 | 3.4 | ||||||||
$ | 5 | 1,118,357 | 0.9 | ||||||||
$ | 5.09 | 341,021 | 0.9 | ||||||||
$ | 1.38 | 50,836 | 2 | ||||||||
$ | 4.16 | 1,000 | 3 | ||||||||
$ | 3.25 | 1,379,571 | 2.6 | ||||||||
$ | 2.12 | 75,000 | 4 | ||||||||
$ | 1.83 | 492,869 | 4 | ||||||||
Total warrants outstanding | 3,553,551 | ||||||||||
Leases_Tables
Leases (Tables) | 3 Months Ended | |||
Dec. 31, 2013 | ||||
Future Minimum Lease Payments Under Capitalized Leases | ' | |||
As of December 31, 2013, future minimum lease payments due in fiscal years under capitalized leases are as follows: | ||||
2014 (remainder of) | $ | 192,634 | ||
2015 | 256,846 | |||
2016 | 256,846 | |||
2017 | 256,846 | |||
2018 | 256,846 | |||
2019 and thereafter | 107,019 | |||
Less interest | (99,294 | ) | ||
Principal | 1,227,743 | |||
Less current portion | (221,345 | ) | ||
Noncurrent portion | $ | 1,006,398 | ||
Future Minimum Lease Payments Under Operating Leases | ' | |||
As of December 31, 2013, future minimum lease payments due in fiscal years under operating leases are as follows: | ||||
2014 (remainder of) | $ | 325,672 | ||
2015 | 445,921 | |||
2016 | 457,961 | |||
2017 | 470,154 | |||
2018 | 359,370 | |||
2019 and thereafter | 125,415 | |||
Total | $ | 2,184,493 | ||
StockBased_Compensation_Tables
Stock-Based Compensation (Tables) | 3 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Summarize Information about Stock Options | ' | |||||||||||||||
The following tables summarize information about stock options: | ||||||||||||||||
Number of | Weighted- | Weighted- | Aggregate | |||||||||||||
Options | Average | Average | Intrinsic | |||||||||||||
Outstanding | Exercise | Remaining | Value | |||||||||||||
Price | Contractual | |||||||||||||||
Per Share | Term | |||||||||||||||
Balance At September 30, 2011 | 729,096 | $ | 9.03 | |||||||||||||
Granted | 1,229,500 | 4.4 | ||||||||||||||
Cancelled | (42,919 | ) | 11.77 | |||||||||||||
Exercised | (4,883 | ) | 5.2 | |||||||||||||
Balance At September 30, 2012 | 1,910,794 | 6.1 | ||||||||||||||
Granted | 1,509,166 | 2.03 | ||||||||||||||
Cancelled | — | — | ||||||||||||||
Exercised | (675 | ) | 3.93 | |||||||||||||
Balance At September 30, 2013 | 3,419,285 | $ | 4.68 | |||||||||||||
Granted | 105,000 | 7.98 | ||||||||||||||
Cancelled | -37,970 | 4.77 | ||||||||||||||
Exercised | -62,825 | 4.83 | ||||||||||||||
Balance At December 31, 2013 | 3,423,490 | $ | 4.77 | 8.1 years | $ | 21,646,786 | ||||||||||
Exercisable At December 31, 2013 | 1,377,779 | $ | 7.25 | 7.6 years | $ | 7,038,191 | ||||||||||
Assumptions Used to Value Stock Options | ' | |||||||||||||||
The assumptions used to value stock options are as follows: | ||||||||||||||||
Three months ended December 31, | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Dividend yield | — | — | ||||||||||||||
Risk-free interest rate | 1.9 | % | 0.7% to 1.0% | |||||||||||||
Volatility | 69 | % | 69 | % | ||||||||||||
Expected life (in years) | 6.25 | 5.5 to 6.25 | ||||||||||||||
Weighted average grant date fair value per share of options granted | $ | 5.06 | $ | 1.51 | ||||||||||||
Fair_Value_Measurements_Tables
Fair Value Measurements (Tables) | 3 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis | ' | |||||||||||||||
The following table summarizes fair value measurements at December 31, 2013 and September 30, 2013 for assets and liabilities measured at fair value on a recurring basis: | ||||||||||||||||
December 31, 2013: | ||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Cash and cash equivalents | $ | 59,713,424 | $ | — | $ | — | $ | 59,713,424 | ||||||||
Derivative assets | $ | — | $ | — | $ | — | $ | — | ||||||||
Derivative liabilities | $ | — | $ | — | $ | 5,097,442 | $ | 5,097,442 | ||||||||
Acquisition related contingent consideration obligations | $ | — | $ | — | $ | 1,595,273 | $ | 1,595,273 | ||||||||
September 30, 2013: | ||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Cash and cash equivalents | $ | 19,114,444 | $ | — | $ | — | $ | 19,114,444 | ||||||||
Derivative assets | $ | — | $ | — | $ | — | $ | — | ||||||||
Derivative liabilities | $ | — | $ | — | $ | 4,096,363 | $ | 4,096,363 | ||||||||
Acquisition related contingent consideration obligations | $ | — | $ | — | $ | 1,595,273 | $ | 1,595,273 | ||||||||
Assumptions Used in Valuing Derivative Asset | ' | |||||||||||||||
The assumptions used in valuing the derivative asset were not applicable as the value has been determined to be zero at December 31, 2013 and September 30, 2013. | ||||||||||||||||
December 31, 2013 | September 30, 2013 | |||||||||||||||
Risk free interest rate | — | — | ||||||||||||||
Expected life | — | — | ||||||||||||||
Dividend yield | — | — | ||||||||||||||
Volatility | — | — | ||||||||||||||
Reconciliation of Derivative Asset | ' | |||||||||||||||
The following is a reconciliation of the derivative asset: | ||||||||||||||||
Value at September 30, 2012 | $ | 250,250 | ||||||||||||||
Receipt of instruments | — | |||||||||||||||
Decrease in value | (250,250 | ) | ||||||||||||||
Net settlements | — | |||||||||||||||
Value at September 30, 2013 | $ | — | ||||||||||||||
Receipt of instruments | — | |||||||||||||||
Decrease in value | — | |||||||||||||||
Net settlements | — | |||||||||||||||
Value at December 31, 2013 | $ | — | ||||||||||||||
Change in Fair Value of Contingent Consideration Obligations | ' | |||||||||||||||
The following is a reconciliation of contingent consideration fair value. | ||||||||||||||||
Value at September 30, 2012 | $ | 173,621 | ||||||||||||||
Purchase price contingent consideration | — | |||||||||||||||
Contingent consideration payments | — | |||||||||||||||
Change in fair value of contingent consideration | 1,421,652 | |||||||||||||||
Value at September 30, 2013 | $ | 1,595,273 | ||||||||||||||
Purchase price contingent consideration | — | |||||||||||||||
Contingent consideration payments | — | |||||||||||||||
Change in fair value of contingent consideration | — | |||||||||||||||
Value at December 31, 2013 | $ | 1,595,273 | ||||||||||||||
Warrant | ' | |||||||||||||||
Assumptions Used in Valuing Derivative Liabilities | ' | |||||||||||||||
The assumptions used in valuing the derivative liability were as follows: | ||||||||||||||||
2010 Warrants | December 31, 2013 | September 30, 2013 | ||||||||||||||
Risk free interest rate | 0.38% | 0.33% | ||||||||||||||
Expected life | 2.0 Years | 2.2 Years | ||||||||||||||
Dividend yield | None | None | ||||||||||||||
Volatility | 69% | 69% | ||||||||||||||
2012 Warrants | 31-Dec-13 | 30-Sep-13 | ||||||||||||||
Risk free interest rate | 1.27% | 1.39% | ||||||||||||||
Expected life | 4.0 Years | 4.2 Years | ||||||||||||||
Dividend yield | None | None | ||||||||||||||
Volatility | 69% | 69% | ||||||||||||||
2013 Warrants | 31-Dec-13 | 30-Sep-13 | ||||||||||||||
Risk free interest rate | 1.27% | 1.39% | ||||||||||||||
Expected life | 4.1 Years | 4.3 Years | ||||||||||||||
Dividend yield | None | None | ||||||||||||||
Volatility | 69% | 69% | ||||||||||||||
Reconciliation of Derivative Liability | ' | |||||||||||||||
The following is a reconciliation of the derivative liability related to these warrants: | ||||||||||||||||
Value at September 30, 2012 | $ | 626,195 | ||||||||||||||
Issuance of instruments | 2,153,819 | |||||||||||||||
Change in value | 5,066,591 | |||||||||||||||
Net settlements | (3,754,808 | ) | ||||||||||||||
Value at September 30, 2013 | $ | 4,091,797 | ||||||||||||||
Issuance of instruments | — | |||||||||||||||
Change in value | 3,507,496 | |||||||||||||||
Net settlements | -2,518,502 | |||||||||||||||
Value at December 31, 2013 | $ | 5,080,791 | ||||||||||||||
Exchange rights | ' | |||||||||||||||
Assumptions Used in Valuing Derivative Liabilities | ' | |||||||||||||||
The assumptions used in valuing the derivative liability were as follows: | ||||||||||||||||
December 31, 2013 | September 30, 2013 | |||||||||||||||
Risk free interest rate | 1.27% | 1.39% | ||||||||||||||
Expected life | 4.0 Years | 4.3 Years | ||||||||||||||
Dividend yield | None | None | ||||||||||||||
Volatility | 69% | 69% | ||||||||||||||
Reconciliation of Derivative Liability | ' | |||||||||||||||
The following is a reconciliation of the derivative liability related to these exchange rights: | ||||||||||||||||
Value at September 30, 2012 | $ | 10,375 | ||||||||||||||
Issuance of instruments | — | |||||||||||||||
Change in value | (5,806 | ) | ||||||||||||||
Net settlements | — | |||||||||||||||
Value at September 30, 2013 | $ | 4,569 | ||||||||||||||
Issuance of instruments | — | |||||||||||||||
Change in value | 12,082 | |||||||||||||||
Net settlements | — | |||||||||||||||
Value at December 31, 2013 | $ | 16,651 | ||||||||||||||
Organization_and_Significant_A2
Organization and Significant Accounting Policies - Additional Information (Detail) (USD $) | 1 Months Ended | 3 Months Ended | 12 Months Ended | 128 Months Ended | |||
31-May-13 | Dec. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2013 | Sep. 30, 2012 | 7-May-03 | |
Schedule Of Investments [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Cash to fund operations | ' | $59,713,424 | $2,931,032 | $19,114,444 | $59,713,424 | $3,377,288 | ' |
Maturity description | ' | 'less than 24 months | ' | ' | ' | ' | ' |
Net increase (decrease) in cash | ' | 40,598,980 | -446,256 | ' | 59,713,424 | ' | ' |
Cash from issuance of equity | 36,000,000 | 60,000,000 | ' | ' | ' | ' | ' |
Net cash invested in fixed income investments | ' | 15,000,000 | ' | ' | ' | ' | ' |
Cash outflow related to continuing operating activities | ' | 7,000,000 | ' | ' | ' | ' | ' |
Capital expenditures | ' | 100,000 | ' | ' | ' | ' | ' |
Restricted Cash | ' | 0 | 0 | ' | 0 | ' | ' |
Amount insured in FDIC per account | ' | 250,000 | ' | ' | 250,000 | ' | ' |
Amortized cost of bonds | ' | 25,750,603 | ' | 10,732,414 | 25,750,603 | ' | ' |
Unrealized Loss on Securities | ' | 217,216 | ' | 41,643 | ' | ' | ' |
Unrealized Gain on Securities | ' | 0 | ' | 7,500 | ' | ' | ' |
Fair value of investments | ' | 25,533,387 | ' | 10,698,271 | 25,533,387 | ' | ' |
Minority equity investment, book value | ' | 0 | ' | ' | 0 | ' | ' |
Minimum | ' | ' | ' | ' | ' | ' | ' |
Schedule Of Investments [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Property, Plant and Equipment, Useful Life | ' | '3 years | ' | ' | ' | ' | ' |
Maximum | ' | ' | ' | ' | ' | ' | ' |
Schedule Of Investments [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Property, Plant and Equipment, Useful Life | ' | '7 years | ' | ' | ' | ' | ' |
Commercial bonds | ' | ' | ' | ' | ' | ' | ' |
Schedule Of Investments [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Maturity description | ' | 'less than 24 months | ' | ' | ' | ' | ' |
Investments | ' | 25,700,000 | ' | ' | 25,700,000 | ' | ' |
Warrants Issued | ' | ' | ' | ' | ' | ' | ' |
Schedule Of Investments [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Cash from exercise of Warrants | ' | $2,800,000 | ' | ' | ' | ' | ' |
Note_Receivable_Additional_Inf
Note Receivable - Additional Information (Detail) (USD $) | 1 Months Ended | 3 Months Ended | |||
In Millions, except Share data, unless otherwise specified | 31-May-13 | Dec. 31, 2013 | Dec. 31, 2013 | Jan. 24, 2013 | Jan. 31, 2011 |
Wisepower | Wisepower | Wisepower | |||
Accounts Notes And Loans Receivable [Line Items] | ' | ' | ' | ' | ' |
Note Receivable, face amount | ' | ' | ' | ' | $2.50 |
Shares received as consideration for the sale of Note | ' | ' | ' | 1,570,000 | ' |
Shares issued under public offering, value | 36 | 60 | 1.4 | ' | ' |
Note receivable future payment, reserve | ' | 1.1 | ' | ' | ' |
Notes receivable, carrying value | ' | ' | $0 | ' | ' |
Investments_Summary_of_Short_a
Investments - Summary of Short and Long-term Investments (Detail) (USD $) | 3 Months Ended | 12 Months Ended |
Dec. 31, 2013 | Sep. 30, 2013 | |
Schedule Of Investments [Line Items] | ' | ' |
Gross Unrealized Gains | $0 | $7,500 |
Gross Unrealized Losses | -217,216 | -41,643 |
Fair Value | 25,533,387 | 10,698,271 |
Commercial notes (due within one year), amortized cost | 15,912,757 | 9,030,261 |
Commercial notes (due after one year through two years, amortized cost | 9,837,846 | 1,702,153 |
Total | 25,750,603 | 10,732,414 |
Commercial Notes Due Within One Year | ' | ' |
Schedule Of Investments [Line Items] | ' | ' |
Gross Unrealized Gains | 0 | 7,500 |
Gross Unrealized Losses | -103,924 | -39,281 |
Fair Value | 15,808,833 | 8,998,480 |
Commercial Notes Due After One Year Through Two Years | ' | ' |
Schedule Of Investments [Line Items] | ' | ' |
Gross Unrealized Gains | 0 | ' |
Gross Unrealized Losses | -113,292 | -2,362 |
Fair Value | $9,724,554 | $1,699,791 |
Acquisitions_Additional_Inform
Acquisitions - Additional Information (Detail) (USD $) | 1 Months Ended | 3 Months Ended | 12 Months Ended | 128 Months Ended | |
Oct. 21, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2013 | |
Business Acquisition [Line Items] | ' | ' | ' | ' | ' |
Obligation to pay royalties | ' | 'later of (i) the expiration of the last to expire patent right related to such product candidate that was transferred in the Transaction and (ii) ten years after the first commercial sale of such product candidate. | ' | ' | ' |
Net present value of contingent consideration | $84,935 | ' | ' | ' | ' |
Contingent consideration - fair value adjustments | ' | ' | ' | 1,400,000 | 1,421,652 |
Roche Madison Inc | ' | ' | ' | ' | ' |
Business Acquisition [Line Items] | ' | ' | ' | ' | ' |
Issue of promissory note to Roche | 50,000 | ' | ' | ' | ' |
Issue of Common Stock | 1,288,158 | ' | ' | ' | ' |
Applicable out-license term | ' | '90 days | ' | ' | '90 days |
Percentage of royalty liability | ' | 3.00% | ' | ' | 3.00% |
Cash payments to Roche, minimum | ' | 2,500,000 | ' | ' | 2,500,000 |
Cash payments to Roche, maximum | ' | $6,000,000 | ' | ' | $6,000,000 |
Intangible_Assets_Schedule_of_
Intangible Assets - Schedule of Intangible Asset (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |
Dec. 31, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | |
Finite Lived And Indefinite Lived Intangible Assets [Line Items] | ' | ' | ' |
Intangible assets not subject to amortization, beginning balance | $3,117,322 | $3,117,322 | ' |
Intangible assets not subject to amortization, Amortization | ' | ' | ' |
Intangible assets not subject to amortization, ending balance | 3,117,322 | 3,117,322 | 3,117,322 |
Intangible assets not subject to amortization, Impairment | ' | ' | ' |
Intangible assets subject to amortization, beginning balance | 123,191 | 1,667,247 | 1,731,211 |
Amortization | -13,663 | -236,009 | -293,964 |
Intangible assets subject to amortization, ending balance | 109,528 | 123,191 | 1,667,247 |
Impairment | ' | -1,308,047 | ' |
Total Intangible assets, beginning balance | 3,240,513 | 4,784,569 | 1,731,211 |
Total Intangible assets, Amortization | -13,663 | -236,009 | -293,964 |
Total Intangible assets, ending balance | 3,226,850 | 3,240,513 | 4,784,569 |
Roche Madison | ' | ' | ' |
Finite Lived And Indefinite Lived Intangible Assets [Line Items] | ' | ' | ' |
Intangible assets not subject to amortization, Additions | ' | ' | 944,935 |
Intangible assets subject to amortization, Additions | ' | ' | 230,000 |
Total Intangible assets, Additions | ' | ' | 1,174,935 |
Alvos Therapeutics | ' | ' | ' |
Finite Lived And Indefinite Lived Intangible Assets [Line Items] | ' | ' | ' |
Intangible assets not subject to amortization, Additions | ' | ' | 2,172,387 |
Intangible assets subject to amortization, Additions | ' | ' | ' |
Total Intangible assets, Additions | ' | ' | $2,172,387 |
Intangible_Assets_Additional_I
Intangible Assets - Additional Information (Detail) (USD $) | 3 Months Ended |
Dec. 31, 2013 | |
Expected Amortization Expense [Line Items] | ' |
Amortization period of intangible assets | '12 years |
Amortization of license agreements in 2014 | $55,000 |
Amortization of license agreements in 2015 | 55,000 |
Amortization of license agreements in 2016 | 13,000 |
Amortization of license agreements, thereafter | $0 |
Licensing Agreements | ' |
Expected Amortization Expense [Line Items] | ' |
Amortization period of intangible assets | '4 years |
Minimum | Patents | ' |
Expected Amortization Expense [Line Items] | ' |
Amortization period of intangible assets | '3 years |
Maximum | Patents | ' |
Expected Amortization Expense [Line Items] | ' |
Amortization period of intangible assets | '20 years |
Investment_in_Subsidiaries_Add
Investment in Subsidiaries - Additional Information (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |
Dec. 31, 2013 | Sep. 30, 2011 | Sep. 30, 2010 | |
Schedule Of Investments [Line Items] | ' | ' | ' |
Ownership percentage in subsidiary | 100.00% | ' | ' |
Issuance of preferred stock in subsidiary | ' | $1,618,509 | $300,000 |
Calando Pharmaceuticals Inc | ' | ' | ' |
Schedule Of Investments [Line Items] | ' | ' | ' |
Outstanding Balance of Promissory Note | 1,167,000 | ' | ' |
Amount owed by subsidiary | 4,500,000 | ' | ' |
Stated percentage of notes and advances | 8.00% | ' | ' |
Percentage of outstanding shares | 79.00% | ' | ' |
Percentage of investment ownership | 76.00% | ' | ' |
Ablaris Therapeutics | ' | ' | ' |
Schedule Of Investments [Line Items] | ' | ' | ' |
Percentage of outstanding shares | 64.00% | ' | ' |
Percentage of investment ownership | 64.00% | ' | ' |
Issuance of preferred stock in subsidiary | ' | 2,900,000 | ' |
Investment in preferred stock | ' | 1,300,000 | ' |
Investment in preferred stock by outsider | ' | $1,600,000 | ' |
Notes_Payable_Additional_Infor
Notes Payable - Additional Information (Detail) (USD $) | 1 Months Ended | 3 Months Ended |
Nov. 26, 2008 | Dec. 31, 2013 | |
Class Of Stock [Line Items] | ' | ' |
Unsecured Convertible Promissory Note Agreements | $2,500,000 | ' |
Investment in Notes offering | 200,000 | ' |
Additional investment in Notes offering | 600,000 | ' |
Principal amount of Note not converted into shares | 500,000 | ' |
Offering Note matured date | ' | 26-Nov-13 |
New Note terms | ' | 'Two times principal payment at maturity |
New note interest rate | 10.00% | ' |
Note interest rate by default | 15.00% | ' |
Offering Note maturity amount | ' | 1,000,000 |
Accrued interest | ' | $167,000 |
Calando | Series A Preferred Stock | ' | ' |
Class Of Stock [Line Items] | ' | ' |
Conversion of Notes and accrued interest in to share | ' | 2,950 |
Stockholders_Equity_Summary_of
Stockholders' Equity - Summary of Information About Warrants (Detail) | Dec. 31, 2013 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 |
Warrant 1 | Warrant 2 | Warrant 3 | Warrant 4 | Warrant 5 | Warrant 6 | Warrant 7 | Warrant 8 | |||
Class Of Warrant Or Right [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise prices | ' | 1.83 | 70.6 | 5 | 5.09 | 1.38 | 4.16 | 3.25 | 2.12 | 1.83 |
Number of Warrants | 3,553,551 | ' | 94,897 | 1,118,357 | 341,021 | 50,836 | 1,000 | 1,379,571 | 75,000 | 492,869 |
Remaining Life in Years | ' | ' | '3 years 4 months 24 days | '10 months 24 days | '10 months 24 days | '2 years | '3 years | '2 years 7 months 6 days | '4 years | '4 years |
Stockholders_Equity_Additional
Stockholders' Equity - Additional Information (Detail) (USD $) | 0 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 128 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | ||||||||||||||||
Oct. 11, 2013 | 31-May-13 | Jan. 31, 2013 | Dec. 31, 2012 | Aug. 10, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2011 | Sep. 30, 2010 | Dec. 31, 2013 | Sep. 30, 2013 | Nov. 17, 2011 | 31-May-13 | Dec. 31, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2010 | Sep. 30, 2005 | Feb. 29, 2012 | Oct. 31, 2011 | Oct. 21, 2011 | Oct. 11, 2013 | 31-May-13 | Oct. 31, 2011 | Oct. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2013 | |
Roche | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Series A Preferred Stock | Series A Preferred Stock | Series A Preferred Stock | Series C Preferred Stock | Series B convertible preferred stock | Subscription Agreement | Subscription Agreement | Limited liability company | 2004 Equity Incentive Plan, 2000 Stock Option Plan, and Inducement Grants | ||||||||||||
Series A Preferred Stock | ||||||||||||||||||||||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Capital stock authorized for issuance | ' | ' | ' | ' | ' | 150,000,000 | ' | ' | ' | 150,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock, shares authorized | ' | ' | ' | ' | ' | 145,000,000 | ' | ' | ' | 145,000,000 | 145,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock, par value | ' | ' | ' | ' | ' | $0.00 | ' | ' | ' | $0.00 | $0.00 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.00 | ' | ' | ' |
Preferred stock, shares authorized | ' | ' | ' | ' | ' | 5,000,000 | ' | ' | ' | 5,000,000 | 5,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred stock, par value | ' | ' | ' | ' | ' | $0.00 | ' | ' | ' | $0.00 | $0.00 | ' | ' | ' | ' | ' | ' | ' | ' | $0.00 | ' | $0.00 | ' | ' | ' | ' | ' | ' |
Common stock, shares outstanding | ' | ' | ' | ' | ' | 39,002,152 | ' | ' | ' | 39,002,152 | 32,489,444 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred stock, shares outstanding | ' | ' | ' | ' | ' | 51,291 | ' | ' | ' | 51,291 | 9,900 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share reserve for issuance | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,451,210 |
Threshold percentage of common stock ownership upon preferred stock conversion | ' | ' | ' | ' | ' | 9.99% | ' | ' | ' | 9.99% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Maximum equity commitment amount under agreement | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $15,000,000 | ' |
Equity commitment agreement period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '36 months | ' |
Cash drawn from facility | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,000,000 | ' |
Sale of stock, price per share | $5.86 | ' | $2.12 | $2.26 | $2.76 | ' | $2.26 | ' | ' | ' | ' | ' | $1.83 | ' | ' | ' | ' | ' | ' | ' | ' | $1,000 | $1,000 | $1,000 | $3.70 | ' | ' | ' |
Aggregate purchase price of preferred shares | ' | ' | ' | ' | ' | ' | ' | 1,618,509 | 300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,015,000 | ' | ' | ' | ' | ' | ' | ' |
Issuance and sold of Common Stock | 3,071,672 | ' | 1,667,051 | 1,825,079 | 2,260,869 | ' | ' | ' | ' | ' | ' | ' | 14,300,000 | 848,961 | 1,182,451 | 15,511 | 8,656 | 225,189 | 1,250 | ' | ' | ' | 46,000 | 9,900 | 675,000 | 1,015 | ' | ' |
Number of shares converted in common stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,015 | 1,015 | ' | ' | ' | ' | ' | ' | ' |
Preferred stock converted to common stock, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 275,782 | ' | ' | ' | ' | ' | ' | ' | ' |
Aggregate purchase price on issuance of common stock to be received | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,497,500 | ' | ' | ' |
Proceeds from issuance of common stock, preferred stock and warrants, net | 60,000,000 | ' | 3,500,000 | 4,100,000 | 6,200,000 | 62,821,592 | 3,332,467 | ' | ' | 213,580,607 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unit sold, description | ' | ' | 'Each unit consisted of one share of common stock and a warrant to purchase | 'Each unit consisted of one share of common stock and a warrant to purchase | 'Each unit consisted of one share of common stock and a warrant to purchase | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrant to purchase share of Common Stock | ' | ' | 0.5 | 0.5 | 0.75 | ' | 0.5 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock exercise price | ' | ' | ' | ' | $3.25 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise price of warrant | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.83 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Conversion price | $5.86 | $1.83 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cash from issuance of equity | ' | 36,000,000 | ' | ' | ' | 60,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Aggregate price on issuance or Sale of equity | $64,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Reverse stock split ratio | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Leases_Future_Minimum_Lease_Pa
Leases - Future Minimum Lease Payments Under Capitalized Leases (Detail) (USD $) | Dec. 31, 2013 | Sep. 30, 2013 |
Capital Leased Assets [Line Items] | ' | ' |
2014 (remainder of) | $192,634 | ' |
2015 | 256,846 | ' |
2016 | 256,846 | ' |
2017 | 256,846 | ' |
2018 | 256,846 | ' |
2019 and thereafter | 107,019 | ' |
Less interest | -99,294 | ' |
Principal | 1,227,743 | ' |
Less current portion | -221,345 | -221,345 |
Noncurrent portion | $1,006,398 | $1,061,113 |
Leases_Future_Minimum_Lease_Pa1
Leases - Future Minimum Lease Payments Under Operating Leases (Detail) (USD $) | Dec. 31, 2013 |
Operating Leased Assets [Line Items] | ' |
2014 (remainder of) | $325,672 |
2015 | 445,921 |
2016 | 457,961 |
2017 | 470,154 |
2018 | 359,370 |
2019 and thereafter | 125,415 |
Total | $2,184,493 |
Leases_Additional_Information_
Leases - Additional Information (Detail) (USD $) | 3 Months Ended | 128 Months Ended | 1 Months Ended | 3 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Aug. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | |
Corporate Headquarters In Pasadena | Research Fcility In Madison | Assets Held under Capital Leases | ||||
Component Of Operating Other Cost And Expense [Line Items] | ' | ' | ' | ' | ' | ' |
Rental expense | ' | ' | $4,790,000 | $13,000 | $22,000 | ' |
Capital lease expiration date | ' | ' | ' | 31-Jan-18 | 28-Feb-19 | ' |
Percentage of increase in annual rental cost | ' | ' | ' | 3.00% | ' | ' |
Rental expenses include common area maintenance and real estate taxes | 13,000 | ' | ' | ' | ' | ' |
Utilities costs per month | 15,000 | ' | ' | ' | ' | ' |
Monthly payments under capital lease | ' | ' | ' | ' | ' | 21,000 |
Increase in total monthly expenditures | 71,000 | ' | ' | ' | ' | ' |
Facility and equipment rent expense | $130,000 | $145,000 | ' | ' | ' | ' |
StockBased_Compensation_Summar
Stock-Based Compensation - Summarize Information about Stock Options (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |
Dec. 31, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ' | ' | ' |
Number of Options Outstanding, beginning balance | 3,419,285 | 1,910,794 | 729,096 |
Number of Options Outstanding, Granted | 105,000 | 1,509,166 | 1,229,500 |
Number of Options Outstanding, Cancelled | -37,970 | ' | -42,919 |
Number of Options Outstanding, Exercised | -62,825 | -675 | -4,883 |
Number of Options Outstanding, ending balance | 3,423,490 | 3,419,285 | 1,910,794 |
Number of Options Outstanding, Exercisable | 1,377,779 | ' | ' |
Weighted Average Exercise Price Per Share, beginning balance | $4.68 | $6.10 | $9.03 |
Weighted Average Exercise Price Per Share, Granted | $7.98 | $2.03 | $4.40 |
Weighted Average Exercise Price Per Share, Cancelled | $4.77 | ' | $11.77 |
Weighted Average Exercise Price Per Share, Exercised | $4.83 | $3.93 | $5.20 |
Weighted Average Exercise Price Per Share, ending balance | $4.77 | $4.68 | $6.10 |
Weighted Average Exercise Price Per Share, Exercisable | $7.25 | ' | ' |
Weighted Average Remaining Contractual Term | '8 years 1 month 6 days | ' | ' |
Weighted Average Remaining Contractual Term, Exercisable | '7 years 7 months 6 days | ' | ' |
Aggregate Intrinsic Value | $21,646,786 | ' | ' |
Aggregate Intrinsic Value, Exercisable | $7,038,191 | ' | ' |
StockBased_Compensation_Assump
Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail) (USD $) | 3 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ' | ' |
Dividend yield | 0.00% | ' |
Risk-free interest rate, minimum | ' | 0.70% |
Risk-free interest rate, maximum | ' | 1.00% |
Risk-free interest rate | 1.90% | ' |
Volatility | 69.00% | 69.00% |
Expected life (in years) | '6 years 3 months | ' |
Weighted average grant date fair value per share of options granted | $5.06 | $1.51 |
Minimum | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ' | ' |
Expected life (in years) | ' | '5 years 6 months |
Maximum | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ' | ' |
Expected life (in years) | ' | '6 years 3 months |
StockBased_Compensation_Additi
Stock-Based Compensation - Additional Information (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |||
Dec. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ' | ' | ' | ' | ' |
Shares reserve for issuance | 395,950 | ' | ' | ' | ' |
Options granted and outstanding to purchase | 3,423,490 | ' | 3,419,285 | 1,910,794 | 729,096 |
Number of Options Outstanding, Granted | 105,000 | ' | 1,509,166 | 1,229,500 | ' |
Options granted outside of Equity Incentive plans | 105,000 | ' | ' | ' | ' |
Stock-based compensation expense | $521,138 | $395,674 | ' | ' | ' |
Fair value of the options granted | 531,510 | 6,083 | ' | ' | ' |
Intrinsic value of the options exercised | 314,858 | 554 | ' | ' | ' |
Dividend yield | 0.00% | ' | ' | ' | ' |
Calando Pharmaceuticals Inc | ' | ' | ' | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ' | ' | ' | ' | ' |
Fair value of the options granted | 0 | 0 | ' | ' | ' |
Pre-tax compensation expense | 28,695 | ' | ' | ' | ' |
Weighted average period to recognize pre-tax compensation expense | '1 year 9 months 18 days | ' | ' | ' | ' |
Arrowhead | ' | ' | ' | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ' | ' | ' | ' | ' |
Pre-tax compensation expense | $5,111,999 | ' | ' | ' | ' |
Weighted average period to recognize pre-tax compensation expense | '3 years | ' | ' | ' | ' |
2000 Stock Option Plan | ' | ' | ' | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ' | ' | ' | ' | ' |
Shares reserve for issuance | 153,200 | ' | ' | ' | ' |
Options granted and outstanding to purchase | 152,900 | ' | ' | ' | ' |
2004 Equity Incentive Plan | ' | ' | ' | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ' | ' | ' | ' | ' |
Shares reserve for issuance | 2,902,360 | ' | ' | ' | ' |
Options granted and outstanding to purchase | 2,874,640 | ' | ' | ' | ' |
Number of Options Outstanding, Granted | 0 | ' | ' | ' | ' |
Fair_Value_Measurements_Fair_V
Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $) | Dec. 31, 2013 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2012 |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ' | ' | ' | ' |
Acquisition related contingent consideration obligations | $1,595,273 | $1,595,273 | $173,621 | $173,621 |
Fair Value, Measurements, Recurring | ' | ' | ' | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ' | ' | ' | ' |
Cash and cash equivalents | 59,713,424 | 19,114,444 | ' | ' |
Derivative assets | ' | ' | ' | ' |
Derivative liabilities | 5,097,442 | 4,096,363 | ' | ' |
Acquisition related contingent consideration obligations | 1,595,273 | 1,595,273 | ' | ' |
Fair Value, Measurements, Recurring | Level 1 | ' | ' | ' | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ' | ' | ' | ' |
Cash and cash equivalents | 59,713,424 | 19,114,444 | ' | ' |
Derivative assets | ' | ' | ' | ' |
Derivative liabilities | ' | ' | ' | ' |
Acquisition related contingent consideration obligations | ' | ' | ' | ' |
Fair Value, Measurements, Recurring | Level 2 | ' | ' | ' | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ' | ' | ' | ' |
Cash and cash equivalents | ' | ' | ' | ' |
Derivative assets | ' | ' | ' | ' |
Derivative liabilities | ' | ' | ' | ' |
Acquisition related contingent consideration obligations | ' | ' | ' | ' |
Fair Value, Measurements, Recurring | Level 3 | ' | ' | ' | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ' | ' | ' | ' |
Cash and cash equivalents | ' | ' | ' | ' |
Derivative assets | ' | ' | ' | ' |
Derivative liabilities | 5,097,442 | 4,096,363 | ' | ' |
Acquisition related contingent consideration obligations | $1,595,273 | $1,595,273 | ' | ' |
Fair_Value_Measurements_Assump
Fair Value Measurements - Assumptions Used in Valuing Derivative Asset (Detail) (Derivative asset) | 3 Months Ended | 12 Months Ended |
Dec. 31, 2013 | Sep. 30, 2013 | |
Derivative asset | ' | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ' | ' |
Risk free interest rate | 0.00% | ' |
Expected life | '0 years | ' |
Dividend yield | 0.00% | ' |
Volatility | 0.00% | ' |
Fair_Value_Measurements_Reconc
Fair Value Measurements - Reconciliation of Derivative Asset (Detail) (Derivative asset, USD $) | 3 Months Ended | 12 Months Ended |
Dec. 31, 2013 | Sep. 30, 2013 | |
Derivative asset | ' | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ' | ' |
Value, Beginning balance | ' | $250,250 |
Receipt of instruments | ' | ' |
Decrease in value | ' | -250,250 |
Net settlements | ' | ' |
Value, Ending balance | ' | ' |
Fair_Value_Measurements_Assump1
Fair Value Measurements - Assumptions Used in Valuing Derivative Liabilities (Detail) | 3 Months Ended | 12 Months Ended |
Dec. 31, 2013 | Sep. 30, 2013 | |
2010 Warrants | ' | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ' | ' |
Risk free interest rate | 0.38% | 0.33% |
Expected life | '2 years | '2 years 2 months 12 days |
Dividend yield | ' | ' |
Volatility | 69.00% | 69.00% |
2012 Warrants | ' | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ' | ' |
Risk free interest rate | 1.27% | 1.39% |
Expected life | '4 years | '4 years 2 months 12 days |
Dividend yield | ' | ' |
Volatility | 69.00% | 69.00% |
2013 Warrants | ' | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ' | ' |
Risk free interest rate | 1.27% | 1.39% |
Expected life | '4 years 1 month 6 days | '4 years 3 months 18 days |
Dividend yield | ' | ' |
Volatility | 69.00% | 69.00% |
Exchange rights | ' | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ' | ' |
Risk free interest rate | 1.27% | 1.39% |
Expected life | '4 years | '4 years 3 months 18 days |
Dividend yield | ' | ' |
Volatility | 69.00% | 69.00% |
Fair_Value_Measurements_Reconc1
Fair Value Measurements - Reconciliation of Derivative Liability (Detail) (USD $) | 3 Months Ended | 12 Months Ended |
Dec. 31, 2013 | Sep. 30, 2013 | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ' | ' |
Change in value | $3,519,579 | ' |
Warrant | ' | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ' | ' |
Value, Beginning balance | 4,091,797 | 626,195 |
Issuance of instruments | ' | 2,153,819 |
Change in value | 3,507,496 | 5,066,591 |
Net settlements | -2,518,502 | -3,754,808 |
Value, Ending balance | 5,080,791 | 4,091,797 |
Exchange rights | ' | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ' | ' |
Value, Beginning balance | 4,569 | 10,375 |
Issuance of instruments | ' | ' |
Change in value | 12,082 | -5,806 |
Net settlements | ' | ' |
Value, Ending balance | $16,651 | $4,569 |
Fair_Value_Measurements_Change
Fair Value Measurements - Change in Fair Value of Contingent Consideration Obligations (Detail) (USD $) | Dec. 31, 2013 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2012 |
Business Acquisition Contingent Consideration [Line Items] | ' | ' | ' | ' |
Value, Beginning balance | $1,595,273 | $1,595,273 | $173,621 | $173,621 |
Purchase price contingent consideration | ' | ' | ' | ' |
Contingent consideration payments | ' | ' | ' | ' |
Change in fair value of contingent consideration | ' | 1,421,652 | ' | ' |
Value, Ending balance | $1,595,273 | $1,595,273 | $173,621 | $173,621 |
Fair_Value_Measurements_Additi
Fair Value Measurements - Additional Information (Detail) (USD $) | 3 Months Ended | 3 Months Ended | 1 Months Ended | ||||||||
Dec. 31, 2013 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Dec. 31, 2013 | Jan. 31, 2011 | Dec. 31, 2013 | Jun. 30, 2010 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Ablaris Therapeutics | Unidym Inc | 2010 Warrants | 2010 Warrants | 2012 Warrants | 2012 Warrants | 2013 Warrants | |||||
Fair Value Measurements Disclosure [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Short term investments | $15,912,757 | $9,030,261 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-term investments | 9,837,846 | 1,702,153 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total investments | 25,750,603 | 10,732,414 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair value of investments | 25,533,387 | 10,698,271 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants issued to acquire Common Stock | ' | ' | ' | ' | ' | ' | ' | 329,649 | ' | 912,543 | 833,530 |
Warrants outstanding | 3,553,551 | ' | ' | ' | ' | ' | 50,836 | ' | 324,461 | ' | 168,408 |
Non-cash gain (loss) from change in fair value of the derivative liability | 3,519,579 | ' | ' | ' | 12,082 | ' | ' | ' | ' | ' | ' |
Duration of exchange rights | '7 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exchange right convertible conversion ratio for first year | ' | ' | ' | ' | 0.06 | ' | ' | ' | ' | ' | ' |
Exchange right convertible conversion ratio for second year | ' | ' | ' | ' | 0.04 | ' | ' | ' | ' | ' | ' |
Exchange right convertible conversion ratio for third year | ' | ' | ' | ' | 0.03 | ' | ' | ' | ' | ' | ' |
Exchange right convertible conversion ratio for fourth year | ' | ' | ' | ' | 0.02 | ' | ' | ' | ' | ' | ' |
Exchange right convertible conversion ratio for fifth year and beyond | ' | ' | ' | ' | 0.01 | ' | ' | ' | ' | ' | ' |
Number of exchange right sold | ' | ' | ' | ' | 675,000 | ' | ' | ' | ' | ' | ' |
Change in value | 3,519,579 | ' | ' | ' | 12,082 | ' | ' | ' | ' | ' | ' |
Acquisition related contingent consideration obligations | 1,595,273 | 1,595,273 | 173,621 | 173,621 | ' | ' | ' | ' | ' | ' | ' |
Non cash consideration received in sale of interest in subsidiary, bonds | ' | ' | ' | ' | ' | $2,500,000 | ' | ' | ' | ' | ' |
Bond convertible conversion price per share | ' | ' | ' | ' | ' | $2 | ' | ' | ' | ' | ' |